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ABSTRACT

The bacterial plant pathogen Pseudomonas Syringae injects
effector proteins into host cells via a type III protein secre
tion system to cause disease. The invention relates to the
discovery that the type III effector HopU1 is a mono-ADP
ribosyltransferase (ADP-RT) and suppresses plant innate
immunity. The HopU1 substrates in Arabidopsis thaliana
extracts were RNA-binding proteins that possess RNA
recognition motifs (RRMs). A. thaliana knock-out lines
defective in the glycine-rich RNA-binding protein AtGRP7,
a HopU1 substrate, were more susceptible than wild type
plants to P syringae. The ADP-ribosylation of AtGRP7 by
HopU1 required two arginines within the RRM. The inven
tion provides novel methods for the modulation of the innate
immune response of a plant to a biotic stress, including
methods for enhancing or suppressing the innate immune
response of the plant.
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USES OF THE PSEUDOMONAS SYRINGAE
EFFECTOR PROTEIN HOPU1 RELATED TO TS
ABILITY TO ADP-RBOSYLATE EUKARYOTC
RNA BINDING PROTEINS
CROSS-REFERENCE TO RELATED
APPLICATIONS

0001. This application claims priority under 35 U.S.C. S
119 of a provisional application Ser. No. 60/804,068 filed
Jun. 6, 2006, which application is hereby incorporated by
reference in its entirety.
GRANT REFERENCE

0002 This invention was made with government support
under NSF Grant No. DBI-0077622, NSF Grant No. MCB
0317165, and NIH Grant No. 1R56AIO69146-01. The Gov

ernment has certain rights in the invention.
FIELD OF THE INVENTION

0003. The present invention provides methods for the
production of plants with enhanced or Suppressed innate
immune responses to a biotic stress.
BACKGROUND OF THE INVENTION

0004 Interactions between bacterial pathogens and their
plant hosts generally fall into two categories: (1) compatible
(pathogen-host), leading to intercellular bacterial growth,
symptom development, and disease development in the host
plant; and (2) incompatible (pathogen-nonhost), resulting in
the hypersensitive response, a particular type of incompat
ible interaction occurring, without progressive disease
symptoms. During compatible interactions on host plants,
bacterial populations increase dramatically and progressive
symptoms occur. During incompatible interactions, bacterial
populations do not increase, and progressive symptoms do
not OCCur.

0005. The hypersensitive response (“HR') is a rapid,
localized necrosis that is associated with the active defense

of plants against many pathogens (Horsfall et al., eds. Plant
Disease: An Advanced Treatise Vol. 5, pp. 201 224, New
York, N.Y.: Academic Press (1980); Mount et al., eds.,
Phytopathogenic Prokaryotes, Vol. 2, pp. 149 177, New
York, N.Y.: Academic Press (1982)). The hypersensitive
response elicited by bacteria is readily observed as a tissue

collapse if high concentrations (~107 cells/ml) of a limited

host-range pathogen like Pseudomonas Syringae or Erwinia
amylovora are infiltrated into the leaves of nonhost plants
(necrosis occurs only in isolated plant cells at lower levels
of inoculum) (Klement, Nature 199:299-300 (1963); Kle
ment et al., Phytopathology 54:474-477 (1963); Turner et
al., Phytopathology 64:885-890 (1974); Mount et al., eds.,
Phytopathogenic Prokaryotes, Vol. 2., pp. 149-177, New
York, N.Y.: Academic Press (1982)). The capacities to elicit
the hyperSensitive response in a nonhost and be pathogenic
in a host appear linked. As noted by Mount et al., eds.,
Phytopathogenic Prokaryotes, Vol. 2., pp. 149 177, New
York, N.Y.: Academic Press (1982), these pathogens also
cause physiologically similar, albeit delayed, necroses in
their interactions with compatible hosts. Furthermore, the
ability to produce the hypersensitive response or pathogen
esis is dependent on a common set of genes, denoted hirp
(Lindgren et al., J. Bacteriol. 168:512-22 (1986); Willis et
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al., Mol. Plant-Microbe Interact. 4:132-138 (1991)). Conse
quently, the hypersensitive response may hold clues to both
the nature of plant defense and the basis for bacterial
pathogenicity.
0006 The hrp genes are widespread in gram-negative
plant pathogens, where they are clustered, conserved, and in
some cases interchangeable (Willis et al., Mol. Plant-Mi
crobe Interact. 4:132-138 (1991); Dangl, ed., Current Topics
in Microbiology and Immunology: Bacterial Pathogenesis
of Plants and -Molecular and Cellular Mechanisms, pp.
79-98, Berlin: Springer-Verlag (1994)). Several hrp genes
encode components of a protein secretion pathway similar to
one used by Yersinia, Shigella, and Salmonella spp. to
secrete proteins essential in animal diseases (Van Gijsegem
et al., Trends Microbiol. 1:175-180 (1993)). In E. amylo
vora, P. syringae, and P Solanacearum, hrp genes have been
shown to control the production and secretion protein elici
tors of the hypersensitive response (He et al., Cell 73:1255
1266 (1993); Wei et al., J. Bacteriol. 175:7958-7967 (1993);
Arlat et al., EMBO J. 13:543-553 (1994)). Hypersensitive
response elicitor proteins, designated harpins, are proteins
found in phytopathogens containing a type III Secretion
system and are typically glycine-rich, acidic, cysteine-lack
ing, heat stable proteins (He et al., Cell 73: 1255-1266
(1993).
0007. The first of these proteins was discovered in E.
amylovora Ea321, a bacterium that causes fire blight of
rosaceous plants, and was designated harpin (Wei et al.,
Science 257:85-88 (1992)). Mutations in the encoding hrpN
gene revealed that harpin is required for E. amylovora to
elicit a hypersensitive response in nonhost tobacco leaves
and incite disease symptoms in highly susceptible pear fruit.
The P solanacearum GMI1000 Pop A1 protein has similar
physical properties and also elicits the hypersensitive
response in leaves of tobacco, which is not a host of that
strain (Arlat et al., EMBO.J. 13:543-53 (1994)). However, P
Solanacearum popA mutants still elicit the hypersensitive
response in tobacco and incite disease in tomato. Thus, the
role of these glycine-rich hypersensitive response elicitors
can vary widely among gram-negative plant pathogens.
0008. Other plant pathogenic hypersensitive response
elicitors have been isolated, cloned, and sequenced from
various organisms, including: HrpW from Erwinia amylo
vora (Kim et al., J. Bacteriol. 180(19):5203-5210 (1998));
HrpN from Erwinia chrysanthemi (Bauer et al., MPMI
8(4):484-91 (1995)); HrpN from Erwinia carotovora (Cuiet
al., MPMI 9(7):565-73 (1996)); HrpN from Erwinia stew
artii (Ahmad et al., 8th Intl. Cong. Molec. Plant-Microb.
Inter. Jul. 14-19, 1996 and Ahmad et al., Ann. Mtg. Am.
Phytopath. Soc. Jul. 27-31, 1996); hreX from Xanthomonas
campestris (U.S. Patent Application Publ. No. 20020066122
to Wei et al.); HrpZ from Pseudomonas Syringae pv. Syrin
gae (He et al., Cell 73:1255-1266 (1993); WO 94/26782 to
Cornell Research Foundation, Inc.); and HrpW from
Pseudomonas Syringae pv. tomato (Charkowski et al., J.
Bacteriol. 180:52.11-5217 (1998)).
0009. Many gram-negative pathogens of plants and other
eukaryotic-associated bacteria utilize type III protein secre
tion systems (T3SSs). (He, S.Y., Nomura, K. & Whittam, T.
S. Type III protein secretion mechanism in mammalian and
plant pathogens. Biochim. Biophys. Acta 1694:181-206
(2004); and Galan, J. E. & Wolf-Watz, H. Protein delivery
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into eukaryotic cells by type III secretion machines. Nature
444:567-573 (2006)). T3SSs are molecular syringes that
inject bacterial proteins called effectors into eukaryotic host
cells to modulate host physiology. In animal cells their
activities alter specific host cell functions including phago
cytosis, proinflammatory responses, apoptosis, and intracel
lular trafficking (Mota, L. J. & Cornelis, G. R. The bacterial
injection kit: type III secretion systems. Ann. Med. 37:234
249 (2005)). Much less is understood about the activities and
targets of type III effectors from plant pathogens. The
emerging picture is that many type III effectors from plant
pathogens Suppress host immune responses (Abramovitch,
R. B., Anderson, J. C. & Martin, G. B. Bacterial elicitation

and evasion of plant innate immunity. Nat. Rev. Mol. Cell.
Biol. 7:601-611 (2006); Espinosa, A. & Alfano, J. R. Dis
abling surveillance: bacterial type III secretion system effec
tors that suppress innate immunity. Cell. Microbiol. 6:1027
1040 (2004); and Mudgett, M. B. New insights to the
function of phytopathogenic bacterial type III effectors in
plants. Annu. Rev. Plant Biol. 56:509-531 (2005)). Thus far,
effectors that possess cysteine protease, tyrosine phos
phatase and E3 ubiquitin ligase activities have been impli
cated in plant innate immunity Suppression (Axtell, M. J. &
Staskawicz, B. J. Initiation of RPS2-specified disease resis
tance in Arabidopsis is coupled to the AvrRpt2-directed
elimination of RIN4. Cell 112:369-377 (2003); Mackey, D.,
Belkhadir, Y. Alonso, J. M., Ecker, J. R. & Dangl, J. L.
Arabidopsis RIN4 is a target of the type III virulence effector
AvrRpt2 and modulates RPS2-mediated resistance. Cell
112:379-389 (2003); Shao, F. et al. Cleavage of Arabidopsis
PBS1 by a bacterial type III effector. Science 301:1230-1233
(2003); Lopez-Solanilla, E., Bronstein, P. A., Schneider, A.
R. & Collmer, A. HopPtoN is a Pseudomonas Syringae Hrp
(type III secretion system) cysteine protease effector that
Suppresses pathogen-induced necrosis associated with both
compatible and incompatible plant interactions. Mol. Micro
biol. 54:353–365 (2004); Bretz, J. R. et al. A translocated
protein tyrosine phosphatase of Pseudomonas Syringae pv.
tomato DC3000 modulates plant defence response to infec
tion. Mol. Microbiol. 49:389-400 (2003); Espinosa, A., Guo,
M., Tam, V.C., Fu, Z. Q. & Alfano, J. R. The Pseudomonas
syringae type III-Secreted protein HopPtol 2 possesses pro
tein tyrosine phosphatase activity and Suppresses pro
grammed cell death in plants. Mol. Microbiol. 49:377-387
(2003); and Janjusevic, R., Abramovitch, R. B., Martin, G.
B. & Stebbins, C. E. A bacterial inhibitor of host pro
grammed cell death defenses is an E3 ubiquitin ligase.
Science 311:222-226 (2006)), however, the enzymatic
activities for most plant pathogen type III effectors that
Suppress innate immunity remain unknown.
BRIEF SUMMARY OF THE INVENTION

0010. The present invention relates to a method of iden
tifying a substrate of HopU1. In one aspect, the identifica
tion is performed in vitro or in vivo. In one aspect, the
substrate is identified from or in a plant or animal cell or
extract. Also included are methods for enhancing the innate
immune response of a plant. In one aspect, the method
includes over-expressing a HopU1 Substrate in a plant cell.
In another aspect, the method includes methods for Sup
pressing the innate immune response of a plant. In one
aspect, the method includes expressing HopU1 in a plant
cell.
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BRIEF DESCRIPTION OF THE DRAWINGS

0011 FIG. 1. HopU1 is a putative mono-ADP-ribosyl
transferase that contributes to virulence. (a) Alignment of the
conserved regions of known mono-ADP-ribosyltransferases
(ADP-RTs) with putative DC3000 ADP-RTS. Conserved
residues are shown underlined and the invariant amino acids

of the CT group of ADP-RTs (Sun, J. & Barbieri, J. T.
Pseudomonas aeruginosa ExoT ADP-ribosylates CT 10
regulator of kinase (Crk) proteins. J. Biol. Chem. 278,
32794-32800 (2003)) are marked with asterisks. (b) hopU1
(white box) is downstream of a type III-related promoter, the
shcP type III chaperone gene, and the hopF2 effector gene
(hatched boxes). (c) RNA was isolated from DC3000 (WT)
or the AhopU1 mutant grown in either rich media (1) or a
minimal medium that induces type III-related genes (2) and
used in RT-PCR reactions. A DNA control (C) and no RT
controls (No RT) were included.
0012 FIG. 2. HopU1 suppresses outputs of plant innate
immunity. (a) DC3000, AhopU1 mutant, and the AhopU1
mutant expressing hopU1 were infiltrated into tobacco

leaves at threshold cell densities (1x10° cells/ml). After 24

h the tissue was assessed for HR production. (b) The
AhopU1 mutant carrying a vector control (pVector), a hopU1
construct (phopU1), or a hopU1 ADP-RT catalytic mutant

construct (phopU1) were infiltrated into tobacco at 1x107

cells/ml and assessed for HR production after 24 h. (c)
Callose deposition was visualized in A. thaliana plants
expressing HopU1-HA or the HopU1-HA mutant 16 h
after treatment with flg22. (d) Callose deposition was quan
tified by counting the number of callose foci per field of
view. Twenty leaf regions (4 fields of view from 5 different
leaves) were averaged and error bars (S.e.m.) are indicated.
The experiment was repeated three times.
0013 FIG. 3. HopU1-His ADP-ribosylates poly-L-argi
nine and proteins in Arabidopsis and tobacco. (a) SDS
PAGE of partially purified HopU1-His and HopU1-His
catalytic mutant (HopU1-His) used in ADP-RT assays.
(b) HopU1-His (stippled bar), HopU1-His (white bar),
and a BSA control (black bar) were incubated with poly-L-

arginine in the presence of PI-NAD. :P-labeled products
ity unit is umole 'P transferred/min/umole of HopU1 times
10'. The experiment was performed twice and the stan

were quantified with liquid scintillation. The specific activ
dard errors are indicated. (c) Autoradiograms of ADP-RT
assays with either Arabidopsis (At) or tobacco (Nt) extracts
with HopU1-His or HopU1-His.
0014 FIG. 4. HopU1-His ADP-ribosylates recombinant
RNA-binding proteins in vitro and in planta. (a) Recombi
nant CP-RBP and GR-RBP glutathione S-transferase (GST)
fusions and a GST control were used in ADP-RT assays with
HopU1-His. ADP-RT reactions were subjected to SDS
PAGE followed by autoradiography. The substrate fusions
are listed with their A. thaliana locus or protein name. (b)
Schematic representation of the RRM and glycine-rich
domains within AtGRP7 and the locations of the arginine
residues (R) throughout the protein. Black and grey sections
within the RRM domain depict RNP1 and RNP2, respec
tively, two conserved regions within RRM domain (Burd, C.
G. & Dreyfuss, G. Conserved structures and diversity of
functions of RNA-binding proteins. Science 265, 615-621
(1994)). The locations of the arginine residues (R) are
indicated. (c) In vitro ADP-RT assays were done with
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HopU1-His and various AtGRP7-GST fusions. These
included an RRM-GST fusion, a glycine-rich domain-GST
fusion, and AtGRP7-GST mutants that have each arginine
within the RRM domain separately substituted with lysine.
Autoradiograms (top panel) indicate the AtGRP7-GST
derivatives that maintained the ability to be ADP-ribosylated
and immunoblots (bottom panel) indicate the relative sta
bility of each AtGRP7-GST derivative. (d) AtGRP7 fused to
an HA epitope (AtGRP7-HA) or an AtGRP7-HA derivative
that is unable to be ADP-ribosylated (AtGRP7Raz-HA)
were transiently expressed in N. benthamiana with HopU1
FLAG or the ADP-RT catalytic mutant HopU1-FLAG.
After 40 h leaf samples were subjected immunoblot analysis
using anti-HA and anti-FLAG antibodies. (a,c) Molecular
mass markers (kDa) are indicated.
0.015 FIG. 5. Analyses of A. thaliana Atgrp7-1 mutant
plants Suggest AtGRP7 plays a role in innate immunity. (a)
Disease symptoms in Atgrp7-1 plants and A. thaliana Col-0

plants after spray-inoculation with at a cell density of 2x10

cells/ml. Pictures were taken after 5 days. The experiments
in b and ‘c’ were repeated five times with similar results.
(b) Bacterial growth assays of wild type DC3000 and the

AhrcC mutant spray-inoculated at a cell density of 2x10

cells/ml onto Atgrp7-1 and wild type A. thaliana Col-0
plants. (c) Callose deposition was determined in A. thaliana
Col-0 and Atgrp7-1 mutant plants 16 h after treatment with
flg22. The number of callose foci per field of view for 20 leaf
regions (4 fields of view from 5 different leaves) were
averaged ts.e.m. The experiment was repeated three times
with similar results.

0016 FIG. 6. HopU1 is injected by the DC3000 T3SS
and contributes to virulence. (a) Adenylate cyclase (CyaA)
assays were carried out by infiltrating DC3000 and a AhrcC
mutant (defective in T3SS) carrying constructs that pro
duced HopU1-CyaA, HopU1-CyaA (HopU1 catalytic
mutant), or AvrPtol-Cya (a type III effector known to be
injected), respectively, into Nicotiana benthamiana. cAMP
levels were determined 10 h after infiltration. (b) Bacterial
strains were inoculated into A. thaliana Col-0 leaves by
dipping plants into bacterial Suspensions.
0017 FIG. 7. Ion leakage conductivity assays to quantify
cell death in the presence of HopU1. (a) DC3000, the
AhopU1 mutant, the AhopU1 mutant expressing hopU1 in
trans (phopU1) were infiltrated into tobacco leaves at thresh
old cell densities and after 24 h conductivity assays were
performed on leaf tissue. The AhopU1 mutant infiltrated leaf
tissue had greater conductivity than leaf tissue infiltrated
with wild type DC3000 consistent with HopU1 acting as an
HR suppressor. (b) The DC3000 AhopU1 mutant carrying
either a vector control (vector), a hopU1 construct
(phopU1), or a hopU1 ADP-RT catalytic mutant construct
(phopU1) were infiltrated into Nicotiana tabacum
(tobacco) at threshold cell densities. Conductivity assays
were carried out after 24 h. When HopU1 was expressed
the conductivity was similar to the DC3000 AhopU1 mutant
indicating the HR suppression ability of HopU1 required a
functional ADP-RT catalytic site.
0018 FIG. 8. HopU1-expressing Arabidopsis plants
elicit a delayed atypical AvrRpt2-dependent HR. A. thaliana
Col-O plants expressing either HopU1-HA or HopU1-HA
were infiltrated with DC3000 with or without the type III
effector gene avrRpt2. After 20 h plants were assessed for
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production of an HR. An HR typically develops in HopU1
HA plants at about 25 h. approximately 10 h longer than it
takes to develop in wild type plants.
0.019 FIG. 9. Representative examples of identification
of protein spots that migrated similarly to ADP-RT activity
spots. (a) An Arabidopsis soluble protein extract was incu

bated with HopU1-His in the presence of 'P-NAD. The

reaction mix was subjected to two-dimensional SDS-PAGE
and stained with Coomassie blue (top panel). The dried
polyacrylamide gel was exposed to autoradiography film
(bottom panel). The black arrowhead in the top panel
identifies a protein that possessed the same migration as an
ADP-ribosylated activity spot in the bottom panel (black
arrowhead). (b) As described in the Methods, a crude A.
thaliana Col-0 extract was separated on a HighTrap Q anion
exchange column and fractions were examined for proteins
that were ADP-ribosylated by HopU1-His. ADP-ribosyl
transferase assays were carried out on all fractions, the
reaction mixtures were subjected to SDS-PAGE, and auto
radiography. Autoradiograms from the fractions that con
tained the majority of HopU1-His substrates based on a high

level of 'P incorporation are shown. (c., d) A. thaliana

extract fractions after ion exchange chromatography were
used in ADP-ribosyltransferase assays and subjected to
two-dimensional SDS-PAGE. Shown are representative gels
(top panel in both c- and d) stained with Coomassie blue and
an autoradiogram (lower panel in both c-d) containing
aliquots from fraction 42 (panel c) or 23 (panel d). The black
arrowheads present in the top panels identify protein spots
that migrated similarly with protein spots that were modified
by HopU1 His in the lower panel. Molecular weight markers
in kilodaltons are indicated on the left (a-d).
0020 FIG. 10. Localization of HopU1-GUS, HopU1
GFP, and substrate GFP fusions in plant cells. (a) Biolistic
transformation of onion epidermal cells was performed with
Agrobacterium binary constructs carrying either the uidA
gene encoding B-glucuronidase (GUS) or the uidA gene
fused to HopU1 (HopU1-GUS). After 24 h the plant tissue
was histochemically stained for GUS activity and photo
graphed. (b-d) hopU1-GFP DNA, DNA encoding HopU1
substrate GFP fusions, or GFP encoding DNA was tran
siently delivered into N. benthamiana leaves with Agrobac
terium-mediated delivery. After 40 h, the leaf tissue was
viewed with confocal microscopy using single excitation
(488 nm) and dual-emission filters (522 nm for GFP and 680
nm for chloroplast autofluorescence). (b) HopU1-GFP or
GFP control merged images are shown. (c) GR-RBP-GFP
fusions are shown. (d) Chloroplast RNA-binding proteins
encoded by the A. thaliana loci At2g37220. 1, AtSg50250.1.
and Atag24770.1 fused to GFP were visualized for GFP (top
panel), and for chloroplast autofluorescence (middle panel).
GFP and autofluorescence images were merged in the bot
tom panel.
0021 FIG. 11. Characterization of a SALK T-DNA
knock-out line designated Atgrp7-1 defective in the AtGRP7
gene. (a) Schematic representation of the AtGRP7 locus in
A. thaliana Col-0 in relation to the T-DNA insertion in

SALK line SALK 039556.21.25.X. Black boxes depict the
two exons (E1 and E2) of AtGRP7; the primers used to
confirm the homozygosity of the Atgrp7-1 mutant (listed in
Table 3 as P2012, P1947, and P2013) are depicted here as
P1, P2, and P3: the T-DNA insertion is represented as a
triangle. (b) PCR with primer set P1/P3, which was used to
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amplify wild type Col-0 DNA, and primer set P1/P2, which
was used to amplify a junction band containing both A.
thaliana DNA and T-DNA confirmed that the Atgrp7-1
mutant is homozygous for the T-DNA insert. (c) Reverse
transcriptase (RT)-PCR with primers (P1932 and P1929 in
Table 3) that anneal to the full length coding sequence
showing that AtGRP7 mRNA was not detectable in the
Atgrp7-1 mutant line. RT-PCR reactions contained RNA
from wild type Col-O plants or the Atgrp7-1 mutant; inclu
sion or exclusion of RT in the reactions is indicated by a +
or '-'. (d) Immunoblot analysis (left panel) of soluble
proteins from leaves of A. thaliana Col-0 and Atgrp7-1
mutant plants using anti-GRP antibodies, which recognizes
AtGRP7. HopU1-His ADP-RT assays were performed with
the same samples. The autoradiogram (right panel) shows
the absence of an ADP-RT high-affinity band in the Atgrp7-1
lane (indicated with an arrow).
0022 FIG. 12. Characterization of a SALK T-DNA
knock-out line designated Atgrp7-2 defective in the AtGRP7
gene. (a) Schematic representation of the AtGRP7 locus in
A. thaliana Col-0 in relation to the T-DNA insertion in

SALK line SALK 051743.42.85.X. Black boxes depict the
two exons (E1 and E2) of AtGRP7; the primers used to
confirm the homozygosity of the Atgrp7-2 mutant (listed in
Table 3 as P2456, P1947, and P2457) are depicted here as
P4, P2, and P5; the T-DNA insertion is represented as a
triangle. (b) PCR with primer set P4/P5, which was used to
amplify wild type Col-0 DNA, and primer set P2/P5, which
was used to amplify a junction band containing both A.
thaliana DNA and T-DNA confirmed that the Atgrp7-2
mutant is homozygous for the T-DNA insert. The junction
band was sequenced and the T-DNA insert was found to be
within the coding region of AtGRP7 in the first exon. This
is a different location than indicated on the SIGnAL website

(http://signal. salk.edu/). (c) Reverse transcriptase (RT)-PCR
with primers (P1932 and P1929 in Table 3) that anneal to the
full length coding sequence showing that AtGRP7 mRNA
was not detectable in the Atgrp7-2 mutant line. RT-PCR
reactions contained RNA from wild type Col-O plants or the
Atgrp7-2 mutant. (d) Immunoblot analysis of soluble pro
teins from leaves of A. thaliana Col-0 and Atgrp7-2 mutant
plants using anti-GRP antibodies, which recognizes
AtGRP7. (e) Bacterial growth assays with wild type P. s.
tomato DC3000 and the AhrcC mutant on wild type A.
thaliana Col-O plants compared to Atgrp7-2 mutant plants.
(f) Disease symptoms on wild type A. thaliana Col-0 and
Atgrp7-2 plants infected with DC3000. Pictures were taken
5 days after spray-inoculation. (g) Callose deposition in A.
thaliana Col-0 and Atgrp7-2 mutant plants 16 h after treat
ment with flg22. The number of callose foci perfield of view
for 20 leaf regions (4 fields of view from 5 different leaves)
were averaged and the standard errors are indicated as error
bars.

0023 FIG. 13. Proposed model of suppression of plant
innate immunity by the HopU1 ADP-RT type III effector. P.
syringae pv. tomato DC3000 injects HopU1 and other type
III effectors into plant cells via its type III secretion system.
Innate immunity can be triggered by a type III effector
(depicted above as the A-labelled diamond) if it is recog
nized directly or indirectly by a resistance (R) protein or by
a PAMP perceived by PAMP receptors (e.g., FLS2). Acti
vated type III effector- and PAMP-triggered signal transduc
tion pathways result in transcriptional changes in the plant
that favor plant resistance to the pathogen. Our model
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predicts that in the absence of HopU1 (U 1) (as in 1), innate
immunity-induced mRNAs are stabilized, transported, or
processed by RNA-binding proteins (RBPs) in the nucleus
or the cytoplasm (as shown) resulting in the production of
immunity-related products that facilitate the outputs of
innate immunity, including the deposition of callose and the
HR. In the presence of HopU1 (as in 2), one or several RBPs
are ADP-ribosylated by HopU1 altering their normal func
tion and, subsequently, affecting RNA metabolism. For
example, the ADP-ribose modification may prevent a RBP
from binding mRNA as depicted. This results in a Sup
pressed innate immune response favoring the Survival of the
pathogen. cw, cell wall; pm, plasma membrane; nm, nuclear
membrane.

0024 FIG. 14. HopU1-His ADP-ribosylates at least one
protein in human cancer cell extracts. ADP-RT reactions

(using P-NAD) were carried out with 34 ug extracts of

22Rv1 human cancer cells and 200 ng of HopU1-His or
HopU1-His. Each reaction was separated with SDS
PAGE and exposed to X-ray film for 10 m.
DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENT

0025. Unless defined otherwise, all technical and scien
tific terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which this
invention belongs. Unless mentioned otherwise, the tech
niques employed or contemplated herein are standard meth
odologies well known to one of ordinary skill in the art. The
materials, methods and examples are illustrative only and
not limiting. The following is presented by way of illustra
tion and is not intended to limit the scope of the invention.
0026. The present inventions now will be described more
fully hereinafter with reference to the accompanying draw
ings, in which some, but not all embodiments of the inven
tion are shown. Indeed, these inventions may be embodied
in many different forms and should not be construed as
limited to the embodiments set forth herein; rather, these

embodiments are provided so that this disclosure will satisfy
applicable legal requirements. Like numbers refer to like
elements throughout.
0027 Many modifications and other embodiments of the
inventions set forth herein will come to mind to one skilled

in the art to which these inventions pertain having the benefit
of the teachings presented in the foregoing descriptions and
the associated drawings. Therefore, it is to be understood
that the inventions are not to be limited to the specific
embodiments disclosed and that modifications and other

embodiments are intended to be included within the scope of
the appended claims. Although specific terms are employed
herein, they are used in a generic and descriptive sense only
and not for purposes of limitation.
Overview

0028. The present invention relates to the discovery that
a Hrp-dependent outer protein (Hop) HopU1 is an adenosine
diphosphate ribosyltransferase (ADP-RT) that acts as a
Suppressor of the innate immune responses of a plant, for
example in Nicotiana tabacum cv. Xanthi (tobacco) or
Arabidopsis thaliana, exposed to a biotic stress. In vitro
studies identified five RNA Binding Protein (RBP) plant
proteins that are ADP-ribosylated by HopU1. Without wish

US 2008/0028487 A1

ing to be bound by this theory, it is believed that expressing
HopU1 in a plant Suppresses innate immunity in a manner
related to HopU1’s ability to ADP-ribosylate a substrate,
thereby interfering with the substrate's ability to bind RNA
and consequently quelling the hosts immunity by affecting
RNA metabolism and the defense transcriptome.
0029 Modulation of the expression level and activity of
HopU1 and its substrates in a plant would provide a mecha
nism for manipulating the plants innate immune response.
Accordingly, the present invention provides methods for the
production of plants with enhanced or Suppressed innate
immune responses, for example, to a biotic stress, Such as a
pathogen. In one aspect, the methods include introducing
into a plant or an animal cell, tissue, or plant one or more
polynucleotides encoding HopU1 polypeptides having the
enzymatic activity of ADP-RT. This may be accomplished
by introducing HopU1 polynucleotides into the plant nuclear
and/or plant plastidial genome.
0030. In one aspect, the methods include introducing into
a plant or animal cell, tissue, plant one or more polynucle
otides encoding HopU1 Substrate polypeptides capable of
being ADP-ribosylated by HopU1. This may be accom
plished by introducing the HopU1 substrate polynucleotide
into the plant nuclear and/or plant plastidial genome.
0031 Plants expressing HopU1 will provide suppressed
innate immune response to a biotic stress. Additionally, they
serve as a system in which to determine the role of targets
of HopU1 and other components in a plants innate immune
response. Advantageously, plants over-expressing a HopU1
Substrate will provide an enhanced innate immune response
to the biotic stress.

0032. The practice of the present invention will employ,
unless otherwise indicated, conventional techniques of
botany, microbiology, tissue culture, molecular biology,
chemistry, biochemistry and recombinant DNA technology,
which are within the skill of the art. Such techniques are
explained fully in the literature. See, e.g., Langenheim and
Thimann, (1982) Botany: Plant Biology and Its Relation to
Human Affairs, John Wiley; Cell Culture and Somatic Cell
Genetics of Plants, vol. 1, Vasil, ed. (1984); Stanier, et al.,

(1986) The Microbial World, 5" ed., Prentice-Hall; Dhringra

and Sinclair, (1985) Basic Plant Pathology Methods, CRC
Press; Maniatis, et al., (1982) Molecular Cloning: A Labo
ratory Manual DNA Cloning, vols. I and II, Glover, ed.
(1985); Oligonucleotide Synthesis, Gait, ed. (1984); Nucleic
Acid Hybridization, Hames and Higgins, eds. (1984); and
the series Methods in Enzymology, Colowick and Kaplan,
eds, Academic Press, Inc., San Diego, Calif.
0033 Units, prefixes, and symbols may be denoted in
their SI accepted form. Unless otherwise indicated, nucleic
acids are written left to right in 5' to 3' orientation; amino
acid sequences are written left to right in amino to carboxy
orientation, respectively. Numeric ranges are inclusive of the
numbers defining the range. Amino acids may be referred to
herein by either their commonly known three letter symbols
or by the one-letter symbols recommended by the IUPAC
IUB Biochemical Nomenclature Commission. Nucleotides,

likewise, may be referred to by their commonly accepted
single-letter codes. The terms defined below are more fully
defined by reference to the specification as a whole.
0034. As used herein, "polynucleotide' includes refer
ence to a deoxyribopolynucleotide, ribopolynucleotide, or
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analogs thereof that have the essential nature of a natural
ribonucleotide in that they hybridize, under stringent hybrid
ization conditions, to Substantially the same nucleotide
sequence as naturally occurring nucleotides and/or allow
translation into the same amino acid(s) as the naturally
occurring nucleotide(s). A polynucleotide can be full-length
or a Subsequence of a native or heterologous structural or
regulatory gene. Unless otherwise indicated, the term
includes reference to the specified sequence as well as the
complementary sequence thereof. Thus, DNAS or RNAs
with backbones modified for stability or for other reasons
are “polynucleotides’ as that term is intended herein. More
over, DNAS or RNAS comprising unusual bases, such as
inosine, or modified bases, such as tritylated bases, to name
just two examples, are polynucleotides as the term is used
herein. It will be appreciated that a great variety of modi
fications have been made to DNA and RNA that serve many
useful purposes known to those of skill in the art. The term
polynucleotide as it is employed herein embraces Such
chemically, enzymatically or metabolically modified forms
of polynucleotides, as well as the chemical forms of DNA
and RNA characteristic of viruses and cells, including inter
alia, simple and complex cells.
0035) Suitable plants for use in methods of the present
invention include but are not limited to, an almond, apple,
apricot, Arabidopsis, artichoke, atriplex, avocado, barley,
beet, birch, brassica, cabbage, cacao, cantaloupe, carna
tions, castorbean, cauliflower, celery, clover, coffee, corn,
cotton, cucumber, garlic, grape, grapefruit, hemp, hops,
lettuce, maple, melon, mustard, oak, oat, olive, onion,
orange, pea, peach, pear, pepper, pine, plum, poplar, potato,
prune, radish, rape, rice, roses, rye, Salicornia, Sorghum,
Soybean, spinach, squash, Strawberries, Sunflower, Sweet
corn, tobacco, tomato or wheat plant. In another aspect, the
term animal includes, but is not limited to, a mouse, cow,

pig, dog, cat, monkey or human.
0036) As used herein, the term “plant includes reference
to an immature or mature whole plant, including a plant that
has been detasseled or from which seed or grain has been
removed. Seed or embryo that will produce the plant is also
considered to be the plant.
0037. The terms “polypeptide,”“peptide,” and “protein'
are used interchangeably herein to refer to a polymer of
amino acid residues. The terms apply to amino acid poly
mers in which one or more amino acid residue is an artificial

chemical analogue of a corresponding naturally occurring
amino acid, as well as to naturally occurring amino acid
polymers.
0038. As used interchangeably herein, a “HopU1 activ
ity”, “biological activity of HopU1 or “functional activity
of HopU1”, refers to an activity exerted by a HopU1 protein,
polypeptide or portion thereofas determined in Vivo, or in
vitro, according to standard techniques. For example,
HopU1 activity includes ADP-ribosylating a substrate in
vitro or in Vivo, or acting to Suppress the innate immune
response of a plant as provided by the present invention.
0039. As used herein, the term HopU1 includes but is not
limited to the sequence of Pseudomonas Syringae pv. tomato
str. DC3000 disclosed in GenBank accession no.

AAO54045.1 GI:28850966 (protein) and AE016853 (nucle
otide). (Buell, Ret al. The complete genome sequence of the
Arabidopsis and tomato pathogen Pseudomonas syringae
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pv. tomato DC3000, Proc. Natl. Acad. Sci. U.S.A.
100(18): 10181-10186 (2003), and also includes conserva
tively modified variants, regardless of source and any other
variants which retain the biological properties of the HopU1,
for example, HopU1 activity. The term “HopU1 polypep
tide' refers to one or more amino acid sequences. The term
is also inclusive of fragments, variants, homologs, alleles or
precursors (e.g., preproproteins or proproteins) thereof. A
“HopU1 protein’ comprises a HopU1 polypeptide. Unless
otherwise stated, the term “HopU1 nucleic acid means a
nucleic acid comprising a polynucleotide (“HopU1 poly
nucleotide') encoding a HopU1 polypeptide.
0040. The term “HopU1 substrate” as used herein refers
to a molecule ADP-ribosylated by a HopU1 protein or
polypeptide. The term “HopU1 substrate polypeptide' refers
to one or more amino acid sequences. The term is also
inclusive of fragments, variants, homologs, alleles or pre
cursors (e.g., preproproteins or proproteins) thereof. A
“HopU1 substrate protein’ comprises a HopU1 substrate
polypeptide. Unless otherwise stated, the term “HopU1
Substrate nucleic acid means a nucleic acid comprising a
polynucleotide (“HopU1 substrate polynucleotide') encod
ing a HopU1 Substrate polypeptide. Exemplary Substrates
include RBPs, such as GR-RBPs and CP-RBPs. HopU1
Substrate polypeptides that are targets of HopU1 Suppress
the innate immune response of a plant when ADP-ribosy
lated by HopU1 or enhance the innate immune system when
over-expressed in a plant cell or plant. It is also contem
plated that certain residues of the HopU1 substrate may be
altered to prevent ADP-ribosylation by HopU1.
0041. The term "suppressing the innate immune
response' as used herein includes making a plants immune
system more Susceptible to a biotic stress for example,
pathogens. Such as bacteria, fungi or viruses, including
microbial invasions. Suppressing the innate immune
response includes decreasing the plants innate immune
response, for example, so that the HR of the plant is
decreased or inhibited upon exposure to a biotic stress. The
Suppression of the innate immune response of a Subject plant
can be determined using a variety of in vitro or in vivo
measurements of innate immune responses to a biotic stress,
for example, including the levels of reactive oxygenation
species (ROS) and nitric oxide (NO), changes in cytoplas
mic Ca2+ levels, production of pathogen-related (PR) gene
expression, phytoalexin production, papillae formation (i.e
thickening of the cell wall), and callose (P-1-3 glucan
deposition) in the cell wall. (Dangl, J. L., and J. D. Jones.
Plant pathogens and integrated defence responses to infec
tion. Nature 411:826-833 (2001); Gomez-Gomez, L., and T.
Boller. Flagellin perception: a paradigm for innate immu
nity. Trends Plant Sci. 7:251-256 (2002); Heath, M. C.
Nonhost resistance and nonspecific plant defenses. Curr.
Opin. Plant Biol. 0.3:315-319 (2000); and Jones, D. A., and
D. Takemoto. Plant innate immunity—direct and indirect
recognition of general and specific pathogen-associated
molecules. Curr. Opin. Immunol. 16:48-62 (2004)), or the
hypersensitive response, present in the plant. (Goodman, R.
N., and A. J. Novacky. The hypersensitive reaction of plants
to pathogens: A resistance phenomenon. APS Press, St. Paul
(1994); and Heath, M. C. Hypersensitive response-related
death. Plant Mol. Biol. 44:321-33 (2000)).
0042. The term "enhancing the innate immune response'
as used herein includes making a plant's immune system
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more resistant to a biotic stress for example, pathogens. Such
as bacteria, fungus or viruses, including microbial invasions.
Enhancing the innate immune response includes increasing
the plants innate immune response, for example, so that the
HR of the plant is increased or maintained upon exposure to
a biotic stress. The enhancement of the innate immune

response of a Subject plant can be determined using a variety
of in vitro or in vivo measurements of innate immune

responses to a biotic stress, for example, including the levels
of reactive oxygenation species (ROS) and nitric oxide
(NO), changes in cytoplasmic Ca2+ levels, production of
pathogen-related (PR) gene expression, phytoalexin produc
tion, papillae formation (i.e. thickening of the cell wall), and
callose (B-1-3 glucan deposition) in the cell wall. (Dangl, J.
L., and J. D. Jones. Plant pathogens and integrated defence
responses to infection. Nature 411:826-833 (2001); Gomez
Gomez, L., and T. Boller. Flagellin perception: a paradigm
for innate immunity. Trends Plant Sci. 7:251-256 (2002);
Heath, M. C. Nonhost resistance and nonspecific plant
defenses. Curr. Opin. Plant Biol. 0.3:315-319 (2000); and
Jones, D. A., and D. Takemoto. Plant innate immunity—
direct and indirect recognition of general and specific patho
gen-associated molecules. Curr. Opin. Immunol. 16:48-62
(2004)), or the hypersensitive response, present in the plant.
(Goodman, R. N., and A. J. Novacky. The hypersensitive
reaction of plants to pathogens: A resistance phenomenon.
APS Press, St. Paul (1994); and Heath, M. C. Hypersensitive
response-related death. Plant Mol. Biol. 44:321-33 (2000)).

0043. The term "hypersensitive response (HR) refers to
a rapid, defense-associated programmed death of plant cells
in contact with the pathogen (Alfano & Collmer, J. Bacte
riol. 179:5655-5662 (1997)).
0044) The term “innate immune response' includes any
response of the immune system including both non-specific
and specific responses.
0045 ADP-ribosylation, as used herein, is a chemical or
biochemical reaction involving the addition of ADP to a
substrate, to form a ribosylated substrate or product.
0046. As used herein, the term “biotic stress' refers to
any pathogen, such as a bacteria, fungi, protozoa and viruses
or any biological organism that is harmful to plants and
includes, an organism oran infectious agent whose infection
around or inside the cells of viable plant tissue elicits a
disease response. Other examples of biotic stresses include
those injuries resulting from infections by insects, nema
todes, Snails, mites, weeds, and physical damage caused by
people (i.e. grazing, tredding, etc.).
0047 A “subject plant or plant cell' is one in which
genetic alteration, such as transformation, has been effected
as to a gene of interest, or is a plant or plant cell which is
descended from a plant cell so altered and which comprises
the alteration. A “control or “control plant’ or “control
plant cell provides a reference point for measuring changes
in phenotype of the Subject plant or plant cell.
0048. A control plant or plant cell may comprise, for
example: (a) a wild-type plant or cell, i.e., of the same
genotype as the starting material for the genetic alteration
which resulted in the subject plant or cell; (b) a plant cell of
the same genotype as the starting material but which has
been transformed with a null construct (i.e. with a construct
which has no known effect on the trait of interest, such as a
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construct comprising a marker gene); (c) a plant or plant cell
which is a non-transformed segregant among progeny of a
Subject plant or plant cell; (d) a plant or plant cell genetically
identical to the subject plant or plant cell but which is not
exposed to conditions or stimuli that would induce the innate
immune response of the plant to a biotic stress; or (e) the
subject plant or plant cell itself, under conditions in which
the gene of interest (HopU1 or HopU1 substrate) is not
expressed.
I. Method of Suppressing the Innate Immune Response of a
Plant.

0049) To date, to the inventor's knowledge, ADP-RTs
have not been implicated in the Suppression of the innate
immune response. Furthermore, genes that encode ADP-RTs
have been found in eukaryotes but have not been identified
in plants (Corda, D. & Di Girolamo, M. Functional aspects
of protein mono-ADP-ribosylation. EMBO 22, 1953-1958
(2003)). In one aspect, the present invention provides a
method for Suppressing the innate immune response of a
plant. In one aspect, the method includes expressing or
over-expressing a polynucleotide that encodes a HopU1
polypeptide with HopU1 activity in a prokaryotic or eukary
otic cell, for example, a bacterial, plant or animal cell. As
used herein, the term “over-express' or “over-expressing
refers to the production of a HopU1 polypeptide in a plant
cell in amounts exceeding that normally produced in the
plant or animal cell.
0050 Polypeptides of HopU1 preferably possess one or
more of the bioactivities of the HopU1 protein, including
ADP-ribosylating a substrate in vitro or in vivo, acting to
Suppress the innate immune response of a plant as provided
by the present invention. Also, included for use in the
present invention are HopU1 substrate polypeptides that are
targets of HopU1 that Suppress the innate immune response
of a plant when ADP-ribosylated by HopU1 or enhance the
innate immune system when over-expressed in a plant cell
or plant. It is also contemplated that certain residues of the
HopU1 substrate may be altered to prevent ADP-ribosyla
tion by HopU1.
0051. In one aspect of the invention, the protein may be
a HopU1 polypeptide, a variant HopU1 polypeptide and/or
have additional amino acid molecules, such as amino acid

residues (contiguous encoded sequence) that are naturally
associated with it or heterologous amino acid residues/
peptide sequences. Such a protein can have a few additional
amino acid residues or can comprise several hundred or
more additional amino acids. Fragments of the HopU1
polypeptide, for example, a fragment that comprises at least
8 or more contiguous amino acid residues from a HopU1
polypeptide or variant protein as described herein, that retain
one or more of the biological activities of a HopU1 polypep
tide, for example, ADP-ribosylating a substrate in vitro or in
Vivo, and/or acting to suppress the innate immune response
of a plant or animal as provided by the present invention.
Also included, therefore, are variants or fragments of the
HopU1 polypeptide that encodes a polypeptide having a
ADP-RT active (catalytic) site, in the conserved region 3
with glutamic acids at positions 233 and 235 (FIG.1a), that
correlates with ribosylation activity of a HopU1 substrate.
Such a domain can be identified on the basis of sequence
similarity with HopU1 ADP-RT domain and other proteins
with ADP-RT domains (e.g., Cholera toxin), especially over
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critical conserved residues. Additional HopU1 polypeptides,
variants or fragments may include those with Substitutions,
deletions, or insertions, as compared to a known sequence,
for example HopU1, including those that alter HopU1
activity.
0052 The polynucleotides encoding polypeptides with
HopU1 activity can be prepared by any suitable technique in
the art, including synthesis or amplification as described in
example 3. As described above, HopU1 polypeptides may be
variants or fragments of HopU1. Any of these can be
attached to heterologous sequences to form chimeric or
fusion proteins for use in methods of the present invention.
Such chimeric and fusion proteins comprise a Hop1
polypeptide operatively linked to a heterologous protein
having an amino acid sequence not substantially homolo
gous to the variant protein. “Operatively linked' indicates
that the variant protein and the heterologous protein are
fused in-frame. The heterologous protein can be fused to the
N-terminus or C-terminus of the HopU1 polypeptide, vari
ant or fragment of HopU1.
0053 A chimeric or fusion protein can be produced by
standard recombinant DNA techniques. For example, DNA
fragments coding for the different protein sequences are
ligated together in-frame in accordance with conventional
techniques. In another embodiment, the fusion gene can be
synthesized by conventional techniques including auto
mated DNA synthesizers. Alternatively, PCR amplification
of gene fragments can be carried out using anchor primers
which give rise to complementary overhangs between two
consecutive gene fragments which can Subsequently be
annealed and re-amplified to generate a chimeric gene
sequence (see Ausubel et al., Current Protocols in Molecular
Biology, 1992). Moreover, many expression vectors are
commercially available that already encode a fusion moiety
(e.g., a GST protein). A variant protein-encoding nucleic
acid can be cloned into Such an expression vector Such that
the fusion moiety is linked in-frame to the variant protein.
0054 Polypeptides sometimes contain amino acids other
than the 20 amino acids commonly referred to as the 20
naturally occurring amino acids. Further, many amino acids,
including the terminal amino acids, may be modified by
natural processes, such as processing and other post-trans
lational modifications, or by chemical modification tech
niques well known in the art. Common modifications that
occur naturally in polypeptides are described in basic texts,
detailed monographs, and the research literature, and they
are well known to those of skill in the art. Accordingly, the
variant peptides of the present invention also encompass
derivatives or analogs in which a Substituted amino acid
residue is not one encoded by the genetic code, in which a
Substitute group is included, in which the mature polypep
tide is fused with another compound. Such as a compound to
increase the half-life of the polypeptide (for example, poly
ethylene glycol), or in which the additional amino acids are
fused to the mature polypeptide, Such as a leader or secretory
sequence or a sequence for purification of the mature
polypeptide or a pro-protein sequence.
0055. The polynucleotides encoding polypeptides with
HopU1 activity can be obtained using methods that are
known to those of skill in the art. Suitable nucleic acids (e.g.,
cDNA, genomic, microRNAs or RNAi, or subsequences)
can be cloned, or amplified by in vitro methods such as the
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polymerase chain reaction (PCR) using Suitable primers, the
ligase chain reaction (LCR), the transcription-based ampli
fication system (TAS), the self-sustained sequence replica
tion system (SSR). A wide variety of cloning and in vitro
amplification methodologies are well-known to persons of
skill. Examples of these techniques and instructions Sufi
cient to direct persons of skill through many cloning exer
cises are found in Berger and Kimmel, Guide to Molecular
Cloning Techniques, Methods in Enzymology 152 Academic
Press, Inc., San Diego, Calif. (Berger); Sambrook et al.
(1989) Molecular Cloning A Laboratory Manual (2nd ed.)
Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring
Harbor Press, NY. (Sambrook et al.); Current Protocols in
Molecular Biology, F. M. Ausubel et al., eds., Current
Protocols, a joint venture between Greene Publishing Asso
ciates, Inc. and John Wiley & Sons, Inc., (1994 Supplement)
(Ausubel); Cashion et al., U.S. Pat. No. 5,017,478; and Carr,
European Patent No. 0.246,864. Examples of techniques
sufficient to direct persons of skill through in vitro ampli
fication methods are found in Berger, Sambrook, and
Ausubel, as well as Mullis et al., (1987) U.S. Pat. No.
4,683.202, PCR Protocols A Guide to Methods and Appli
cations (Innis et al., eds) Academic Press Inc. San Diego,
Calif. (1990) (Innis); Amheim & Levinson (Oct. 1, 1990)
C&EN 36-47: The Journal Of NIH Research (1991) 3:81–
94; (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173:
Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87: 1874;
Lomell et al. (1989).J. Clin. Chem., 35:1826; Landegren et
al., (1988) Science 241:1077-1080; Van Brunt (1990) Bio
technology 8:291-294: Wu and Wallace (1989) Gene 4:560;
and Barringer et al. (1990) Gene 89:117.
0056. One of skill would recognize that modifications
could be made to a HopU1 or HopU1 substrate polypeptide
or protein without diminishing its biological activity. Some
modifications may be made to facilitate the cloning, expres
Sion, or incorporation of the targeting molecule into a fusion
protein. Such modifications are well known to those of skill
in the art and include, for example, a methionine added at the
amino terminus to provide an initiation site, or additional
amino acids (e.g., poly His) placed on either terminus to
create conveniently located restriction sites or termination
codons or purification sequences.
0057 Modifications to the HopU1 or HopU1 substrate
polypeptide or protein also include but are not limited to
conservative amino acid substitutions and those that are

Ophenotypically silent. Conservative substitutions are the
replacements, one for another, among the aliphatic amino
acids Ala, Val, Leu, and Ile; interchange of the hydroxyl
residues Ser and Thr, exchange of the acidic residues Asp
and Glu, substitution between the amide residues Asn and

Gln, exchange of the basic residues Lys and Arg and
replacements among the aromatic residues Phe, Tyr and Trp.
Guidance concerning which amino acid changes are likely to
be phenotypically silent is found in Bowie et al., Science
247: 1306 1310 (1990).
0.058 Expression cassettes and vectors and in vitro cul
ture methods for plant cell or tissue transformation and
regeneration of plants are known and available. See, e.g.,
Gruber et al., “Vectors for Plant Transformation,” in Meth

ods in Plant Molecular Biology and Biotechnology, Supra,
pp. 89-119. A polynucleotide encoding a polypeptide with
HopU1 activity or a HopU1 substrate may be introduced
into either a prokaryotic or eukaryotic plant or animal host
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cell through the use of a vector, plasmid or construct, or
TTSS, such as P. Syringae or P aeruginosa. An expression
cassette may contain a promoter operably linked to a nucleic
acid that encodes the polypeptide. Cells are transfected with
an expression vector for the polynucleotide encoding a
polypeptide with HopU1 activity or a HopU1 substrate, or
variant or fragment thereof, and if desired the effect on ADP
ribosylation may be measured by a suitable method, such as
the assays described herein. The expression cassettes are
typically included on expression vectors that are introduced
into Suitable host cells, including for example, bacterial,
insect, fungal, plant or animal cells. For example, plant
expression vectors may include a cloned plant gene under
the transcriptional control of 5' and 3' regulatory sequences
and a dominant selectable marker. Such plant expression
vectors may also contain, if desired, a promoter regulatory
region (e.g., one conferring inducible or constitutive, envi
ronmentally- or developmentally-regulated, or cell- or tis
Sue-specific/selective expression), a transcription initiation
start site, a ribosome binding site, an RNA processing signal,
a transcription termination site, and/or a polyadenylation
signal.
0059. The expression vectors of the invention can be
transferred into the chosen eukaryotic host cell by methods
known to those of ordinary skill in the art including, for
example, calcium phosphate transfection, DEAE-dextran
mediated transfection, transvection, microinjection, cationic
lipid-mediated transfection, electroporation, transduction,
scrape loading, ballistic introduction, infection, Methods To
Get Into Plant Cells or other methods. (See Molecule Clon

ing: A Laboratory Manual, 2" ed., Vol. 1-3, ed. Sambrook

et al., Cold Spring Harbor Laboratory Press (1989)). Trans
formed cells can be selected, for example, by resistance to
antibiotics conferred by genes contained on the plasmids,
Such as the amp, gpt, neo and hyg genes.
0060 Numerous methods for introducing foreign genes
into plants are known and can be used to insert a HopU1 or
HopU1 Substrate polynucleotide into a plant host, including
biological and physical plant transformation protocols. See,
e.g., Miki et al., “Procedure for Introducing Foreign DNA
into Plants, in Methods in Plant Molecular Biology and
Biotechnology, Glick and Thompson, eds. CRC Press, Inc.,
Boca Raton, pp. 67-88 (1993). The methods chosen vary
with the host plant, and include chemical transfection meth
ods such as calcium phosphate, microorganism-mediated
gene transfer Such as Agrobacterium (Horsch et al., Science
227: 1229-31 (1985)), electroporation, micro-injection, and
biolistic bombardment.

0061 Transformation protocols as well as protocols for
introducing polypeptides or polynucleotide sequences into
plants may vary depending on the type of plant or plant cell,
i.e., monocot or dicot, targeted for transformation. Suitable
methods of introducing polypeptides and polynucleotides
into plant cells include microinjection (Crossway et al.
(1986) Biotechniques 5:320–335), electroporation (Riggs et
al. (1986) Proc. Natl. Acad. Sci. USA 83:5602-5606, Agro
bacterium-mediated transformation (Townsend et al., U.S.
Pat. No. 5,563,055; Zhao et al., U.S. Pat. No. 5,981,850),
direct gene transfer (Paszkowski et al. (1985) EMBO J.
3:2717-2722), and ballistic particle acceleration (see, for
example, Sanford et al., U.S. Pat. No. 5,955.050; Tomes et
al., U.S. Pat. No. 5,879,918: Tomes et al., U.S. Pat. No.

5,886.255; Bidney et al., U.S. Pat. No. 5,932,782; Tomes et
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al. (1995) “Direct DNA Transfer into Intact Plant Cells via
Microprojectile Bombardment,” in Plant Cell, Tissue, and
Organ Culture. Fundamental Methods, ed. Gamborg and
Phillips (Springer-Verlag, Berlin); McCabe et al. (1988)
Biotechnology 6:923-926); and Lec1 transformation
(WO00/28058). Also see Weissinger et al. (1988) Ann. Rev.
Genet. 22:521-577; Sanford et al. (1987) Particulate Science
and Technology 5:27-37 (onion); Christou et al. (1988) Plant
Physiol. 87:671-675 (soybean); McCabe et al. (1988) Bio/
Technology 6:923-926 (soybean); Finer and McMullen
(1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean);
Singh et al. (1998) Theor. Appl. Genet. 96:319-325 (soy
bean); Datta et al. (1990) Biotechnology 8:736-750 (rice);
Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:5305-5309
(maize): Klein et al. (1988) Biotechnology 6:559-563
(maize): Tomes, U.S. Pat. No. 5.250,855; Buising et al., U.S.
Pat. Nos. 5,322,783 and 5.325,656: Tomes et al. (1995)
“Direct DNA Transfer into Intact Plant Cells via Micro

projectile Bombardment,” in Plant Cell, Tissue, and Organ
Culture Fundamental Methods, ed. Gamborg (Springer
Verlag, Berlin) (maize): Klein et al. (1988) Plant Physiol.
91:550-555 (maize): Fromm et al. (1990) Biotechnology
8:833-839 (maize): Hooykaas-Van Slogteren et al. (1985)
Nature (London) 311:763-765: Bowen et al., U.S. Pat. No.
5,736,369 (cereals); Bytebier et al. (1987) Proc. Natl. Acad.
Sci. USA 85:5355-5359 (Liliaceae); De Wet et al. (1985) in
The Experimental Manipulation of Ovule Tissues, ed. Chap
man et al. (Longman, New York), pp. 197-209 (pollen);
Kaeppler et al. (1990) Plant Cell Reports 9:515-518 and
Kaeppler et al. (1992) Theor. Appl. Genet. 85:560-566
(whisker-mediated transformation); D Halluin et al. (1992)
Plant Cell 5:1595-1505 (electroporation); Li et al. (1993)
Plant Cell Reports 12:250-255 and Christou and Ford
(1995) Annals of Botany 75:507-513 (rice); Osjoda et al.
(1996) Nature Biotechnology 15:755-750 (maize via Agro
bacterium tumefaciens); Leelavathi et al. (2004) Plant Cell
Reports 22:465-470 (cotton via Agrobacterium tumefa
ciens); Kumar et al. (2004) Plant Molecular Biology 56:203
216 (cotton plastid via bombardment); all of which are
herein incorporated by reference.
0062. As used herein “promoter' includes reference to a
region of DNA upstream from the start of transcription and
involved in recognition and binding of RNA polymerase and
other proteins to initiate transcription. A “plant promoter is
a promoter capable of initiating transcription in plant cells.
Exemplary plant promoters include, but are not limited to,
those that are obtained from plants, plant viruses, and
bacteria which comprise genes expressed in plant cells Such
Agrobacterium or Rhizobium. Examples are promoters that
preferentially initiate transcription in certain tissues. Such as
leaves, roots, seeds, fibers, Xylem vessels, tracheids, or
sclerenchyma. Such promoters are referred to as “tissue
preferred. A “cell type' specific promoter primarily drives
expression in certain cell types in one or more organs, for
example, vascular cells in roots or leaves. An “inducible' or
“regulatable' promoter is a promoter, which is under envi
ronmental control. Examples of environmental conditions
that may effect transcription by inducible promoters include
anaerobic conditions or the presence of light.
0063 Another type of promoter is a developmentally
regulated promoter, for example, a promoter that drives
expression during pollen development. Examples of pollens
specific promoters include but are not limited to a pollen
specific pectate lyase gene promoter or PG47 gene promoter,
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an another specific RTS2 gene promoter, SGB6 gene pro
moter, or G9 gene promoter. Tissue preferred, cell type
specific, developmentally regulated, and inducible promot
ers constitute the class of “non-constitutive' promoters. A
“constitutive' promoter is a promoter, which is active under
most environmental conditions. Induced expression can also
be achieved using chemicals such as estradiol using induc
ible vector Per8 (Jianru Zuo, Qi-Wen Niu, Nam-Hai Chua
(2000) An estrogen receptor-based transactivator XVE
mediates highly inducible gene expression in transgenic
plants. The Plant Journal 24 (2), 265-273. doi:10.1046/
j.1365-313x2000.00868.x).

0064. A number of promoters can be used in the practice
of the invention, including the native promoter of the HopU1
or HopU1 Substrate polynucleotide sequence, for example,
the promoter of the HopU1 substrate of the crop plant of
interest. The promoters can be selected based on the desired
outcome. The HopU1 or HopU1 substrate polynucleotide
can be combined with constitutive, tissue-preferred, induc
ible, or other promoters for expression in plants.
0065. A plant promoter or promoter fragment can be
employed which will direct expression of a polynucleotide
of the present invention in all tissues of a regenerated plant.
Such promoters are referred to herein as “constitutive'
promoters and are active under most environmental condi
tions and states of development or cell differentiation.
Examples of constitutive promoters include the 1'- or 2'-pro
moter derived from T-DNA of Agrobacterium tumefaciens,
the Smas promoter, the cinnamyl alcohol dehydrogenase
promoter (U.S. Pat. No. 5,683.439), the Nos promoter, the
rubisco promoter, the GRP1-8 promoter, the 35S promoter
from cauliflower mosaic virus (CaMV), as described in
Odell, et al., (1985) Nature 313:810-2: rice actin (McElroy,
et al., (1990) Plant Cell 163-171); ubiquitin (Christensen, et
al., (1992) Plant Mol. Biol. 12:619-632 and Christensen, et
al., (1992) Plant Mol. Biol. 18:675-89); pEMU (Last, et al.,
(1991) Theor: Appl. Genet. 81:581-8); MAS (Velten, et al.,
(1984) EMBO.J. 3:2723-30); and maize H3 histone (Lepetit,
et al., (1992) Mol. Gen. Genet. 231:276-85; and Atanassvoa,
et al., (1992) Plant Journal 2(3):291-300); ALS promoter, as
described in PCT Application No. WO 96/30530; and other
transcription initiation regions from various plant genes
known to those of skill. For the present invention ubiquitin
is the preferred promoter for expression in monocot plants.
0066 Tissue-preferred promoters can be utilized to target
enhanced type A RR expression within a particular plant
tissue. By “tissue-preferred' is intended to mean that expres
sion is predominately in a particular tissue, albeit not nec
essarily exclusively in that tissue. Tissue-preferred promot
ers include Yamamoto et al. (1997) Plant J. 12(2):255-265;
Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803;
Hansen et al. (1997) Mol. Gen. Genet. 255(3):337-353;
Russellet al. (1997) Transgenic Res. 6(2): 157-168; Rinehart
et al. (1996) Plant Physiol. 112(3):1331-1351; Van Camp et
al. (1996) Plant Physiol. 112(2):525-535; Canevascini et al.
(1996) Plant Physiol. 112(2):513-525; Yamamoto et al.
(1995) Plant Cell Physiol. 35(5):773-778; Lam (1995)
Results Probl. Cell Differ. 20:181-196; Orozco et al. (1993)
Plant Mol. Biol. 23(6): 1129-1138; Matsuoka et al. (1993)
Proc Natl. Acad. Sci. USA 90(20):9586-9590; and Guevara
Garcia et al. (1993) Plant J. 5(3):595-505. Such promoters
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can be modified, if necessary, for weak expression. See, also,
U.S. Patent Application No. 2003/0074698, herein incorpo
rated by reference.
0067 Expression of HopU1 and over-expression of
HopU1 substrates may be achieved by any number of
methods, including but not limited to transient transfection,
integration, gene amplification, plant transformation or any
other molecular process which results in amounts of HopU1
polypeptide exceeding those amounts typically found in the
host cell as described elsewhere in the application. The
typical range of expression in a given cell type can be
determined by routine techniques as by assaying the HopU1
protein, its mRNA, or its gene.
0068. The expression level of the HopU1 or HopU1
Substrate polypeptide may be measured directly, for
example, by assaying for the level of the HopU1 or HopU1
Substrate polypeptide in the plant, or indirectly, for example,
by measuring the HopU1 activity of the HopU1 or HopU1
substrate polypeptide in the plant. Methods for determining
the HopU1 or HopU1 substrate expression or activity may
be determined using standard techniques or assays such as
immunoassay, PAGE, western blot, Southern and Northern
blots, and competition hybridization procedures and Y.
including the evaluation of ADP-RT activity in vitro or in
Vivo in various expression systems.
0069. Functional assays for ADP-ribosyltransferase can
be conducted by incubating the HopU1 polypeptide with a
target protein (such as the poly-L-arginine (see Example 7)),
or a known substrate of HopU1, such as AtGRP7 and
AtGRP8 (See Table 1) in the presence of nicotinamide
adenine dinucleotide (NAD"), or an analog labeled with a

radioisotope such as

P or

P. biotin, or a fluorescent

group. (186) ADP-ribosylation can be monitored by incor
poration of the label into the protein phase, by a change of
size of the target protein (measurable, for example on a
protein gel), or by detection of ADP ribose polymers on the
target (for example, using commercially available antibody
specific for ADP-ribose polymers, or by physical-chemical
mechanisms, such as mass spectrometry). Known ADP-RT
inhibitors like novobiocin can be used to verify the speci
ficity of the assay. Polypeptides with confirmed ADP-RT
activity can then be used in methods of the present inven
tion, for example, Suppressing the innate immune system of
a plant.
0070 The evaluation of HopU1 expression may also
include evaluation of phenotypic changes. Such as Sup
pressed immune response in a plant Subjected to a biotic
stress. Examples of phenotypic changes include but are not
limited to the transfer of ADP-ribose of B-NAD onto a
HopU1 substrate, HR and other outputs of innate immunity
as described herein. As stated above, Suppression of the
plants innate immune response may be achieved through
expression of HopU1. Thus, modulation of HopU1 expres
sion or activity in a plant or plant cell provides a novel
strategy for Suppressing the immune system of a plant
exposed to a biotic stress.
0071 Methods are provided to reduce or eliminate the
level and/or the activity of a HopU1 substrate polypeptide
by transforming a plant cell with an expression cassette that
expresses a polynucleotide that inhibits the expression of the
HopU1 substrate polypeptide. As used herein, the term
“under-express”, “under-expression' or “under-expressing

refers to the production of a HopU1 substrate polypeptide in
a plant cell in amounts less than that normally produced in
the plant or animal cell.
0072 The polynucleotide may inhibit the expression of
one or more HopU1 substrate polypeptides directly, by
preventing translation of the HopU1 Substrate messenger
RNA, or indirectly, by encoding a polypeptide that inhibits
the transcription or translation of a plant gene encoding a
HopU1 substrate polypeptide. Methods for inhibiting or
eliminating the expression of a gene in a plant are well
known in the art, and any Such method may be used in the
present invention to inhibit the expression of one or more
HopU1 substrate polypeptide.
0073. In accordance with the present invention, the
expression of a HopU1 substrate polypeptide is under
expressed, decreased or inhibited if the protein level of the
HopU1 Substrate polypeptide is statistically significantly
lower than the protein level of the same HopU1 substrate
polypeptide in a plant that has not been genetically modified
or mutagenized to inhibit the expression of that protein. In
particular embodiments of the invention, the protein level of
the HopU1 substrate polypeptide in a modified plant accord
ing to the invention is less than 96%, less than 90%, less than
80%, less than 75%, less than 60%, less than 50%, less than
40%, less than 30%, less than 20%, less than 10%, or less

than 5% of the protein level of the same HopU1 substrate
polypeptide in a plant that is not a mutant or that has not
been genetically modified to inhibit the expression of that
HopU1 substrate polypeptide. The expression level of the
HopU1 substrate polypeptide may be measured directly, for
example, by assaying for the level of HopU1 substrate
polypeptide expressed in the plant cell or plant, or indirectly,
for example, by measuring the activity of the HopU1 sub
strate polypeptide in the plant cell or plant. Methods for
determining the HopU1 substrate activity of HopU1 sub
strate polypeptide are described elsewhere herein.
0074. In other embodiments of the invention, the activity
of one or more HopU1 substrate is reduced or eliminated by
transforming a plant cell with an expression cassette com
prising a polynucleotide encoding a polypeptide that inhibits
the activity of one or more HopU1 substrates. The HopU1
Substrate activity may be inhibited according to the present
invention if the HopU1 substrate activity of the genetically
modified plant is statistically significantly lower than the
activity of the same HopU1 substrate in a plant that has not
been genetically modified to inhibit the HopU1 substrate
activity. In particular embodiments of the invention, the
HopU1 substrate activity of the HopU1 substrate in a
modified plant according to the invention is less than 95%,
less than 90%, less than 80%, less than 70%, less than 60%,
less than 50%, less than 40%, less than 30%, less than 20%,

less than 10%, or less than 5% of the HopU1 substrate
activity of the same HopU1 substrate in a plant that that has
not been genetically modified to inhibit the expression of
that HopU1 substrate. The HopU1 substrate activity of a
HopU1 substrate is “eliminated according to the invention
when it is not detectable by the assay methods described
elsewhere herein. Methods of determining the HopU1 sub
strate activity of a HopU1 substrate are described elsewhere
herein.

0075). In other embodiments, the activity of a HopU1
substrate may be reduced or eliminated by disrupting the
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gene encoding the HopU1 Substrate. The invention encom
passes mutagenized plants that carry mutations in HopU1
Substrate genes, where the mutations reduce expression of
the HopU1 substrate gene or inhibit the HopU1 substrate
activity of the encoded HopU1 substrate.
0.076 Thus, many methods may be used to reduce or
eliminate the activity of a HopU1 substrate. More than one
method may be used to reduce the activity of a single HopU1
Substrate. In addition, combinations of methods may be
employed to reduce or eliminate the activity of two or more
different HopU1 substrate polypeptides.
0077. Non-limiting examples of methods of reducing or
eliminating the expression of a HopU1 Substrate are given
below.

0078. In some embodiments of the present invention, a
plant cell is transformed with an expression cassette that is
capable of expressing a polynucleotide that inhibits the
expression of HopU1 substrate polypeptides. The term
“expression” as used herein refers to the biosynthesis of a
gene product, including the transcription and/or translation
of said gene product. For example, for the purposes of the
present invention, an expression cassette capable of express
ing a polynucleotide that inhibits the expression of at least
one HopU1 Substrate polypeptide is an expression cassette
capable of producing an RNA molecule that inhibits the
transcription and/or translation of at least one HopU1 sub
strate polypeptide. The “expression' or “production of a
protein or polypeptide from a DNA molecule refers to the
transcription and translation of the coding sequence to
produce the protein or polypeptide, while the “expression
or “production of a protein or polypeptide from an RNA
molecule refers to the translation of the RNA coding
sequence to produce the protein or polypeptide.
0079. In some embodiments of the invention, inhibition
of the expression of a HopU1 substrate polypeptide may be
obtained by sense Suppression or coSuppression. For coSup
pression, an expression cassette is designed to express an
RNA molecule corresponding to all or part of a messenger
RNA encoding a HopU1 substrate polypeptide in the
“sense' orientation. Over-expression of the RNA molecule
can result in reduced expression of the native gene. Accord
ingly, multiple plant lines transformed with the coSuppres
sion expression cassette are screened to identify those that
show the greatest inhibition of HopU1 substrate polypeptide
expression.
0080. The polynucleotide used for cosuppression may
correspond to all or part of the sequence encoding the
HopU1 substrate polypeptide, all or part of the 5' and/or 3'
untranslated region of a HopU1 Substrate transcript, or all or
part of both the coding sequence and the untranslated
regions of a transcript encoding HopU1 Substrate polypep
tide. In some embodiments where the polynucleotide com
prises all or part of the coding region for the HopU1
Substrate polypeptide, the expression cassette is designed to
eliminate the start codon of the polynucleotide so that no
protein product will be transcribed.
0081 Cosuppression may be used to inhibit the expres
sion of plant genes to produce plants having undetectable
protein levels for the proteins encoded by these genes. See,
for example, Broin et al. (2002) Plant Cell 15:1517-1532.
CoSuppression may also be used to inhibit the expression of
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multiple proteins in the same plant. See, for example, U.S.
Pat. No. 5,952,657. Methods for using cosuppression to
inhibit the expression of endogenous genes in plants are
described in Flavellet al. (1995) Proc. Natl. Acad. Sci. USA
91:3590-3596: Jorgensen et al. (1996) Plant Mol. Biol.
31:957-973: Johansen and Carrington (2001) Plant Physiol.
126:930-938: Broin et al. (2002) Plant Cell 15:1517-1532:
Stoutjesdijk et al (2002) Plant Physiol. 129: 1723-1731: Yu
et al. (2003) Phytochemistry 63:753-763; and U.S. Pat. Nos.
5,035,323, 5,283,185, and 5,952,657; each of which is

herein incorporated by reference. The efficiency of cosup
pression may be increased by including a poly-dT region in
the expression cassette at a position 3' to the sense sequence
and 5' of the polyadenylation signal. See, U.S. Patent
Publication No. 20020058815, herein incorporated by ref
erence. Typically, such a nucleotide sequence has substantial
sequence identity to the sequence of the transcript of the
endogenous gene, optimally greater than about 65%
sequence identity, more optimally greater than about 85%
sequence identity, most optimally greater than about 95%
sequence identity. See, U.S. Pat. Nos. 5.283,185 and 5,035,
323; herein incorporated by reference.
0082 Transcriptional gene silencing (TGS) may be
accomplished through use of hpRNA constructs wherein the
inverted repeat of the hairpin shares sequence identity with
the promoter region of a gene to be silenced. Processing of
the hpRNA into short RNAs which can interact with the
homologous promoter region may trigger degradation or
methylation to result in silencing. (Aufsatz et al. (2002)
PNAS 99 (Suppl. 4): 16499-16506; Mette et al. (2000)
EMBOJ 19(19):5194-5201) See also U.S. Patent Publica

tion 2005/0246796.

0083. In some embodiments of the invention, inhibition
of the expression of the HopU1 substrate polypeptide may
be obtained by antisense Suppression. For antisense Suppres
Sion, the expression cassette is designed to express an RNA
molecule complementary to all or part of a messenger RNA
encoding the HopU1 substrate polypeptide. Over-expression
of the antisense RNA molecule can result in reduced expres
sion of the native gene. Accordingly, multiple plant lines
transformed with the antisense Suppression expression cas
sette are screened to identify those that show the greatest
inhibition of HopU1 substrate polypeptide expression.
0084. The polynucleotide for use in antisense suppres
sion may correspond to all or part of the complement of the
sequence encoding the HopU1 Substrate polypeptide, all or
part of the complement of the 5' and/or 3' untranslated region
of the HopU1 substrate polypeptide transcript, or all or part
of the complement of both the coding sequence and the
untranslated regions of a transcript encoding the HopU1
Substrate polypeptide. In addition, the antisense polynucle
otide may be fully complementary (i.e., 100% identical to
the complement of the target sequence) or partially comple
mentary (i.e., less than 100% identical to the complement of
the target sequence) to the target sequence. Antisense Sup
pression may be used to inhibit the expression of multiple
proteins in the same plant. See, for example, U.S. Pat. No.
5,952,657. Furthermore, portions of the antisense nucle
otides may be used to disrupt the expression of the target
gene. Generally, sequences of at least 50 nucleotides, 100
nucleotides, 200 nucleotides, 300, 400, 450, 500, 550, or

greater may be used. Methods for using antisense Suppres
sion to inhibit the expression of endogenous genes in plants
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are described, for example, in Liu et al (2002) Plant Physiol.
129: 1732-1753 and U.S. Pat. Nos. 5,759,829 and 5,952,657.

Efficiency of antisense Suppression may be increased by
including a poly-dT region in the expression cassette at a
position 3' to the antisense sequence and 5' of the polyade
nylation signal. See U.S. Patent Publication No. 2002/
O058815.

0085. In some embodiments of the invention, inhibition
of the expression of a HopU1 substrate polypeptide may be
obtained by double-stranded RNA (dsRNA) interference.
For dsRNA interference, a sense RNA molecule like that

described above for cosuppression and an antisense RNA
molecule that is fully or partially complementary to the
sense RNA molecule are expressed in the same cell, result
ing in inhibition of the expression of the corresponding
endogenous messenger RNA.
0.086 Expression of the sense and antisense molecules
can be accomplished by designing the expression cassette to
comprise both a sense sequence and an antisense sequence.
Alternatively, separate expression cassettes may be used for
the sense and antisense sequences. Multiple plant lines
transformed with the dsRNA interference expression cas
sette or expression cassettes are then screened to identify
plant lines that show the greatest inhibition of HopU1
substrate polypeptide expression. Methods for using dsRNA
interference to inhibit the expression of endogenous plant
genes are described in Waterhouse et al. (1998) Proc. Natl.
Acad. Sci. USA 95:13959-13965, Liu et al. (2002) Plant
Physiol. 129:1732-1753, and WO 99/59029, WO 99/53050,
WO99/61631, and WO 00/59035.

0087. In some embodiments of the invention, inhibition
of the expression of one or more type A RR polypeptide may
be obtained by hairpin RNA (hpRNA) interference or intron
containing hairpin RNA (ihpRNA) interference. These
methods are highly efficient at inhibiting the expression of
endogenous genes. See, Waterhouse and Helliwell (2003)
Nat. Rev. Genet. 5:29-38 and the references cited therein.

0088 For hpRNA interference, the expression cassette is
designed to express a RNA molecule that hybridizes with
itself to form a hairpin structure that comprises a single
Stranded loop region and a base-paired stem. The base
paired stem region comprises a sense sequence correspond
ing to all or part of the endogenous messenger RNA
encoding the gene whose expression is to be inhibited, and
an antisense sequence that is fully or partially complemen
tary to the sense sequence. Thus, the base-paired stem region
of the molecule generally determines the specificity of the
RNA interference. hpRNA molecules are highly efficient at
inhibiting the expression of endogenous genes, and the RNA
interference they induce is inherited by Subsequent genera
tions of plants. See, for example, Chuang and Meyerowitz
(2000) Proc. Natl. Acad. Sci. USA 97:5985-5990; Stoutes
dijk et al. (2002) Plant Physiol. 129: 1723-1731; and Water
house and Helliwell (2003) Nat. Rev. Genet. 5:29-38. Meth
ods for using hpRNA interference to inhibit or silence the
expression of genes are described, for example, in Chuang
and Meyerowitz (2000) Proc. Natl. Acad. Sci. USA 97:5985
5990; Stoutjesdijk et al. (2002) Plant Physiol. 129: 1723
1731: Waterhouse and Helliwell (2003) Nat. Rev. Genet.
5:29-38; Pandolfini et al. BMC Biotechnology 3:7, and U.S.
Patent Publication No. 2003.0175965; each of which is

herein incorporated by reference. A transient assay for the
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efficiency of hpRNA constructs to silence gene expression in
vivo has been described by Panstruga et al. (2003) Mol. Biol.
Rep. 30:135-150.
0089 For ihpRNA, the interfering molecules have the
same general structure as for hpRNA, but the RNA molecule
additionally comprises an intron that is capable of being
spliced in the cell in which the ihpRNA is expressed. The use
of an intron minimizes the size of the loop in the hairpin
RNA molecule following splicing, and this increases the
efficiency of interference. See, for example, Smith et al.
(2000) Nature 507:319-320. In fact, Smith et al. show 100%
Suppression of endogenous gene expression using ihpRNA
mediated interference. Methods for using ihpRNA interfer
ence to inhibit the expression of endogenous plant genes are
described, for example, in Smith et al. (2000) Nature
507:319-320; Wesley et al. (2001) Plant J. 27:581-590;
Wang and Waterhouse (2001) Curr. Opin. Plant Biol. 5:156
150; Waterhouse and Helliwell (2003) Nat. Rev. Genet.
5:29-38: Helliwell and Waterhouse (2003) Methods 30:289
295, and U.S. Patent Publication No. 20030180955.

0090 The expression cassette for hpRNA interference
may also be designed Such that the sense sequence and the
antisense sequence do not correspond to an endogenous
RNA. In this embodiment, the sense and antisense sequence
flank a loop sequence that comprises a nucleotide sequence
corresponding to all or part of the endogenous messenger
RNA of the target gene. Thus, it is the loop region that
determines the specificity of the RNA interference. See, for
example, WO 02/00905.
0091 Suppression or enhancement of the immune
response of a plant to a biotic stress may be determined or
inferred from evaluating outputs of innate immunity, using
any number of methods including those as described herein.
See Example 7. Once animal or plant immune systems
perceive biotic stresses, such as PAMPs or AVR proteins or
other viral, fungal, and bacterial pathogens, signal transduc
tion pathways are triggered and defense-related outputs are
deployed. Examples of physiological responses that occur in
plants after activation of innate immunity include the gen
eration of reactive oxygenation species (ROS) and nitric
oxide (NO), changes in cytoplasmic Ca2+ levels, production
of pathogen-related (PR) gene expression, phytoalexin pro
duction, papillae formation (i.e. thickening of the cell wall),
and callose (B-1-3 glucan deposition) in the cell wall.
(Dangl, J. L., and J. D. Jones. Plant pathogens and integrated
defence responses to infection. Nature 411:826-833 (2001);
Gomez-Gomez, L., and T. Boller. Flagellin perception: a
paradigm for innate immunity. Trends Plant Sci. 7:251-256
(2002); Heath, M. C. Nonhost resistance and nonspecific
plant defenses. Curr. Opin. Plant Biol. 0.3:315-319 (2000);
and Jones, D. A., and D. Takemoto. Plant innate immunity—
direct and indirect recognition of general and specific patho
gen-associated molecules. Curr. Opin. Immunol. 16:48-62
(2004)), or the hyperSensitive response, a programmed cell
death response similar to apoptosis in. (Goodman, R.N., and
A. J. Novacky. The hypersensitive reaction of plants to
pathogens: A resistance phenomenon. APS Press, St. Paul
(1994); and Heath, M. C. Hypersensitive response-related
death. Plant Mol. Biol. 44:321-33 (2000)).
0092 Plants expressing or over-expressing HopU1 and/
or those with under-expressed or decreased levels of one or
more HopU1 substrates are exposed to or challenged with a
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biotic stress, for example, viral, fungal, and bacterial patho
gens such as P. syringae tomato DC3000, Oomycete patho
gen Peronospora parasitica (that causes Downy mildew), of
flg22 and the Suppression of the innate immune system
determined. Suppression of the innate immune system of a
plant by HopU1 may be determined by evaluating callose
deposition in a plant cell wall in a plant exposed to a biotic
stress. Callose may be easily stained with a fluorescent dye
aniline blue and levels assessed accordingly. (Adam, L., and
S. C. Somerville. Genetic characterization of five powdery
mildew disease resistance loci in Arabidopsis thaliana Plant
J. 9:341-356 (1996)). Plants expressing or over-expressing
HopU1, for example, HopU1 transgenic plants, will produce
reduced amounts of callose, for example, significantly
reduced amounts of callose, as compared to a control plant.
The control plant may be a plant that does not have the
expression or over-expression of HopU1 or one that is only
exposed to a biotic stress.
0093. Another way in which to evaluate the suppression
of the innate immune system of a plant is through the
production of reactive oxygen species (ROS). (Mittler, R.
Oxidative stress, antioxidants and stress tolerance. Trends

Plant Sci. 7:405-410 (2002)). Levels of ROS may be deter
mined in plants or exposed to a biotic stress using any
suitable technique, including but not limited to nitroblue
tetrazolium (NBT) based assays or fluoroscent probe dichlo
rohydrofluorescein diacetate (DCF-DA). NBT is a dye that
form an insoluble blue precipitate in the presence of ROS
that can be easily viewed. Leaves of a plant expressing or
over-expressing HopU1 and exposed to the biotic stress may
be painted with a solution of NBT as described in 33
(Cessna, S. G. V. E. Sears, M. B. Dickman, and P. S. Low.
Oxalic acid, a pathogenicity factor for Sclerotinia Sclerotio
rum, suppresses the oxidative burst of the host plant. Plant
Cell 12:2191-2200 (2000)). Likewise, DCF-DA is oxidized
by ROS in cells and yields the green fluoroscent product
DCF that can be viewed with fluorescence microscopy.
(LeBel, C. P. H. Ischiropoulos, and S. C. Bondy. Evaluation
of the probe 2,7'-dichlorofluorescin as an indicator of reac
tive oxygen species formation and oxidative stress. Chem.
Res. Toxicol. 5:227-231 (1992)). Plants expressing or over
expressing HopU1, for example, HopU1 transgenic plants,
may produce reduced amounts of ROS, for example, Sig
nificantly reduced amounts of ROS, as compared to a control
plant. The control plant may be a plant that does not have the
expression or over-expression of HopU1 or one that is not
exposed to a biotic stress. The proper positive and negative
controls will be known to one of skill in the art.

0094 Optionally, plants expressing HopU1 polypeptides
and/or those with under-expressed or decreased levels of one
or more HopU1 substrates may be evaluated for the disease
symptoms of the pathogen and their ability to grow in these
plants using standard techniques known in the art. (Petnicki
Ocwieja, T., D. J. Schneider, V. C. Tam, S. T. Chancey, L.
Shan, Y. Jamir, L. M. Schechter, M. D. Janes, C. R. Buell,

X. Tang, A. Collmer, and J. R. Alfano. Genomewide iden
tification of proteins secreted by the Hrp type III protein
secretion system of Pseudomonas Syringae pv. tomato
DC3000. Proc. Natl. Acad. Sci. USA99:7652-7657 (2002);
and Wehling, M.D., M. Guo, Z. Q. Fu, and J. R. Alfano. The
Pseudomonas Syringae HopPtoV protein is secreted in cul
ture and translocated into plant cells via the type III protein
secretion system in a manner dependent on the ShcV type III
chaperone. J. Bacteriol. 186:3621-3630 (2004)). For
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example, diseases symptoms and multiplication of the
pathogen in planta may be determined at various time points
as a measure of whether or not innate immunity is Sup
pressed by over-expression of HopU1 in a plant and/or those
plants with decreased levels of one or more HopU1 sub
Strates.

0095 HopU1 is less similar to other known Hops, shar
ing only 21% identity to HopO1-1 and HopO1-2; however,
additional polypeptides having HopU1 activity may be
identified according to the invention. Those skilled in the art
will readily appreciate that the assays described earlier in
this section can be adapted to screen for other polypeptides
that have HopU1 activity that may be involved in suppress
ing the immune response, for example, to a biotic stress.
This can be determined using a variety of methods and
assays routine to one skilled in the art, for example, deter
mining the ADP-ribosylation of a substrate of HopU1.
Generally, a purified or partially purified candidate HopU1
polypeptide is incubated with a peptide comprising the
ADP-ribosylation target sequence of HopU1 under condi
tions suitable for the HopU1 to ribosylate its target sequence
of amino acids (i.e., protein, polypeptide). The particular
conditions of the ADP-ribosylation may be determined
empirically by one of skill in the art, or using the conditions
that are described herein. The extent of ribosylation of the
target Substrate peptide is determined in the presence and
absence of the candidate HopU1 polypeptide.
0096. Known HopU1 polynucleotides can be used to
identify additional HopU1 polynucleotides in a sample of
interest, for example by Northern, Southern or Western blot
analysis. Polypeptides are conveniently obtained by trans
lation in an in vitro translation system, or by expression in
a suitable host cell. To produce an expression vector, a
polynucleotide encoding the desired polypeptide is operably
linked to control elements for transcription and translation,
and then transfected into a suitable host cell. Expression may
be effected in prokaryotes such as E. coli, eukaryotic micro
organisms such as the yeast Saccharomyces cerevisiae, or
higher eukaryotes, such as plant, insect or mammalian cells.
Following production, the protein is typically purified from
the producing host cell by standard methods in protein
chemistry in an appropriate combination, which may include
ion exchange chromatography, affinity chromatography, and
HPLC. Expression products are optionally produced with a
sequence tag to facilitate affinity purification, which can
Subsequently be removed by proteolytic cleavage.
0097 Such polypeptides can be tested, including but not
limited to the characterization of Suppression of the immune
response, assays for the identification of HopU1 ADP-RT
activity. Variants, fragments or domains of HopU1 polypep
tides can be assessed for HopU1 activity and employed in
the methods of the present invention.
0098. In another example, HopU1 is labeled with a
traceable Substituent, such as biotin, a fluorescent group, an
enzyme, a radioisotope, or a peptide group (e.g., FLG, HA,
myc, or an immunoreactive peptide sequence), and then
combined in a reaction Solution with an isolated candidate

binding partner, or with a mixture of components (such as a
cell extract) in which compounds with HopU1 binding
activity may be found. Formation of complexes with the
labeled HopU1 is then detected (for example, by gel shift
techniques or immunoprecipitation), and correlated with
binding activity for HopU1.
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0099 Another approach is a co-expression system, using
HopU1, a HopU1 fragment, or a candidate HopU1 polypep
tide as bait. For example, a yeast two-hybrid Screen system
is employed, in which a HopU1 encoding sequence is fused
to one part of the expression system, and a library of
candidate binding partners is fused to the complementary
component needed for expression of the marker. Cloned
cells that express the activity of the marker contain an insert
that comprises the encoding sequence for a HopU1 binding
partner. Yeast two-hybrid screen systems are described gen
erally in Bianchi et al., EMBO J., 16:1785, 1997. Reagents
and suitable libraries are commercially available.
II. Method of Enhancing the Innate Immune Response of a
Plant.

0100. The invention is related to the discovery of HopU1
substrates and the use of these substrates for the enhance

ment of the innate immune response of a plant to a biotic
stress. Exemplary HopU1 substrates are RNA-binding pro
teins (RBPs) that are glycine-rich RNA-biding proteins
(GR-RBPs) and chloroplast RNA-biding proteins (CP
RBPs). The HopU1 substrates ADP-ribosylated by HopU1
were identified in Arabidopsis thaliana and include three
CP-RBPs and two glycine-rich RNA-binding proteins (GR
RBPs). (See Table 1). To the inventor's knowledge, RNA
binding proteins have not been described as a substrate for
any ADP-RT, much less, HopU1.
0101. In one aspect, the invention provides for a method
of enhancing an innate immune system of a plant to a biotic
stress. In one aspect, the method includes over-expressing a
HopU1 substrate in a plant. In one aspect, the HopU1
substrate is a RNA binding protein, including but not limited
to a glycine rich RNA binding protein or a chloroplast RNA
binding protein. The HopU1 substrate is capable of being
ADP-ribosylated by HopU1. It is also contemplated that
certain residues of the HopU1 substrate may be altered to
prevent ADP-ribosylation by HopU1, including those
located within the RRM. Such residues include arginines
and may be located within the RBP's RNA-recognition
motif (RRM).
0102 RNA binding proteins have a conserved RNA
Recognition Motif (RRM). Chloroplast RNA binding pro
teins may have two RRMs and glycine rich RNA binding
proteins may only have one RRM. The first RRM of
cp29-like Chloroplast RBP (At2g,377220.1) is from position
92 to position 165 and the second RRM is from position 205
to position 278. The first RRM of cp31-like Chloroplast RBP
(At5g,50250.1) is from position 114 to position 187 and the
second RRM is from position 207 to position 291. The first
RRM of AtRBP31 Chloroplast RBP (Atag2477.1) is from
position 151 to position 224 and the second RRM would be
from position 245 to 318. The RRM can be found from
position 9 to position 82 in AtGRP7 (At2g21660.1) and
position 7 to position 80 in AtGRP8 (Atag39260.1).
0103) The HopU1 substrate when over-expressed in a
plant will enhance the innate immune response of a plant
that is subjected to a biotic stress. Examples of HopU1
substrates include but are not limited to cp29-like Chloro
plast RBP (At2g377220.1) (accession numbers for protein
and nucleotides are NP 181259 and NM 129278.3 respec
tively), cp31-like Chloroplast RBP (At5g,50250.1) (acces
sion numbers for protein and nucleotide are NP 199836
and NM 124404.3, respectively). At RBP31 Chloroplast
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RBP (Atag2477.1) (accession numbers for protein and
nucleotide are NP 194208 and NM 118610.3, respec
tively), Arabidopsis glycine rich RNA binding proteins
AtGRP7 (accession numbers for the protein and nucleotide
are NP 179760 and NM 127738, respectively), glycine
rich RNA binding protein. At GRP8 (Atag39260.1) (acces
sion numbers for protein and nucleotide are NP 195637
and NM 120087.3, respectively) and variants thereof,
including conserved amino acid Substitutions.
0104. As described above, a polynucleotide of a HopU1
Substrate may be introduced into either a prokaryotic or
eukaryotic plant or animal host cell through the use of a
vector, plasmid or construct. An expression cassette con
taining a promoter operably linked to a nucleic acid that
encodes the HopU1 substrate may be introduced into suit
able host cells, including for example, bacterial, insect,
fungal, plant or animal cells. Either constitutive, induced, or
regulated promoters can be used in the present invention.
Promoters suitable for use in eukaryotic host cells are well
known to those of skill in the art and are described elsewhere

in the specification.
0105 Additional HopU1 substrates may be isolated or
identified from any suitable source, for example, from
genomic or cDNA libraries, plant extracts, or plant or animal
cells. Extracts may be from any plant, dicot or monocot,
Such as rice, wheat, corn, tomato, corn, soybean, Sunflower,
Sorghum, canola, alfalfa, cotton, barley or millet. Extracts
may be from any plant, insect, yeast, or mammalian cells.
Examples of mammalian cells also include those cells that
grow in cell culture, such as HeLa, 22RV1 (human prostatic
cells), and 293T cells and the like. In one aspect, HopU1
substrates may be identified either in vivo or in vitro using
any number of methods.
0106 Functional assays for ADP-ribosyltransferase can
be conducted by incubating the HopU1 polypeptide with a
candidate HopU1 Substrate or an extract Suspected of con
taining a HopU1 Substrate (see Example 7)), in the presence

of NAD" or an analog labeled with a radioisotope such as

P. biotin, or a fluorescent group. (Sun, J., and J. T. Barbieri.
Pseudomonas aeruginosa ExoT ADP-ribosylates CT 10
regulator of kinase (Crk) proteins. J. Biol. Chem.
278:32794-32800 (2003)). Substrates that contain the bioti
nylated NAD+ may be isolated and concentrated with avidin
affinity chromatography and identified. (Zhang, J. Use of
biotinylated NAD to label and purify ADP-ribosylated pro
teins. Methods Enzymol. 280:255-265 (1997); and Zhang,
J., and S. H. Snyder. Purification of a nitric oxide-stimulated
ADP-ribosylated protein using biotinylated beta-nicotina
mide adenine

dinucleotide.

Biochem.

32:2228-2233

(1993)).
0.107 ADP-ribosylation can be monitored by incorpora
tion of the label into the protein phase, by a change of size
of the target protein (measurable, for example on a protein
gel), or by detection of ADP ribose polymers on the target
(for example, using commercially available antibody spe
cific for ADP-ribose polymers, or by physical-chemical
mechanisms, such as mass spectrometry). Known ADP-RT
inhibitors like novobiocin can be used to verify the speci
ficity of the assay. Polypeptides with confirmed ADP-RT
ribosylation can then be used in methods of the present
invention, for example, enhancing the innate immune sys
tem of a plant or further characterized. For example, two
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dimensional PAGE may be performed on ADP-RT reactions
and detected for example by autoradiology. Radiolabled
spots may be isolated from the gel and digested with
enzymes Such as endopeptidases and analyzed with tandem
mass spectrometry to identify the HopU1 substrate. The
cDNAs of the identified HopU1 substrates may be isolated
or amplified from the plant or animal nucleic acids, a nucleic
acid library, or produced by synthetic chemistry. The poly
nucleotide sequence of the HopU1 substrate may be inserted
into any of the many available expression vectors and cell
systems using reagents that are well known in the art. For
example, HopU1 Substrate sequences may be ligated into a
GST fusion vector, transformed in bacteria and purified with
glutathione Sepharose and subjected to in vitro ADP-RT
assays with HopU1, for example, HopU1 His as described in
Example 3. Two-dimensional PAGE and autoradiology be
performed on the reactions to determine whether the candi
date HopU1 substrates were ADP-ribosylated by HopU1 in
vitro.

0108. In one aspect, mammalian substrates of HopU1
may be identified using any of methods described herein or
known to one skilled in the art. For example, extracts from
mammalian cells may be added to an ADP-RT reaction mix
containing HopU1, for example, HopU1 His or HopU1
His and then the samples separated, using for example, a
SDS-PAGE. Ribosylation may be detected as described
herein, including exposing ADP-RT reactions separated by
SDS-PAGE to film where protein bands may be detected and
further analyzed. (See FIG. 14 which shows a protein band
of about 29 kDa that was ADP-ribosylated in a HopU1
dependent manner. The molecular mass of this ADP-ribo
sylated protein is similar to several of the substrates that
were ADP-ribosylated in plant extracts by HopU1. Mam
malian substrates of HopU1 may be identified in vitro and in
Vivo experiments, using for example, heterologous delivery
of HopU1 into animal cells via the P. aeruginosa TTSS. In
another aspect, the method includes localizing HopU1 and
its substrates to determine if they co-localize. The Barbieri
protocol may be used for preparing the cell line extracts,
which includes an acetone precipitation step. 1. Sun, J., and
J. T. Barbieri. 2003. Pseudomonas aeruginosa ExoT ADP
ribosylates CT10 regulator of kinase (Crk) proteins. J. Biol.

Chem. 278:32794-32800.

P-NAD ART (ADP-ribosyl

transferase) assays may be performed as described herein
above and subjected to 2D SDS-PAGE and autoradiography.
Protein spots that align with ADP-RT activity spots may be
identified using MALDI-TOF and Q-TOF MS. Mammalian
HopU1 substrates include but are not limited to RNA
binding proteins.
0109. In another aspect, the HopU1 substrates are sub
strates of HopU1 identified in planta. The ADP-ribosylation
of substrates by HopU1 can be determined using transient
expression in a plant, for example, in Nicotiana benthami
ana using binary vectors that express a HopU1 polypeptide
and a HopU1 substrate or a candidate HopU1 substrate. The
HopU1 polypeptide and HopU1 substrate or a candidate
HopU1 substrate may contain epitopes for detection by
antibodies as necessary, for example, HA, FLAG, HopU1,
GRP-RBP or CP-RBP antibodies. Extracts from the tran

siently expressed plant may be analyzed by using a combi
nation of SDS-PAGE gels and immunoblots using antibod
ies that recognize the HopU1 polypeptide and HopU1
substrate or a candidate HopU1 substrate, for example, HA,
FLAG, HopU1, GRP-RBP or CP-RBP antibodies. If a

substrate is ADP-ribosylated by HopU1, the substrate's
molecular mass would be expected to increase by 541 Da
increments (the molecular mass of ADP-ribose) as indicated
by a shift in mobility.
0110. In another aspect, the HopU1 substrates are sub

strates of HopU1 identified in vivo. In one aspect, P

labeled NAD+ is introduced into plant suspension or mam
malian cultured cells that express HopU1 and then extracts
from these cells are analyzed with SDS-PAGE and autora
diography. (Sun, J., and J. T. Barbieri. Pseudomonas aerugi
nosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk)
proteins. J. Biol. Chem. 278:32794-32800 (2003)). Protein

spots that co-migrate with the Plabeled proteins may be

identified using mass spectrometry.
0111. In one aspect, a polypeptide, variant or fragment of
the HopU1 substrate may be over-expressed in a plant. The
HopU1 substrate that is to be over-expressed may be
mutated in its amino acid residues that are suspected or
known to be ribosylated by HopU1 so that the HopU1
substrate is notable to be modified by HopU1. For example,
the number of amino acid residues that are ADP-ribosylated
may be determined using mass spectrometry. HopU1 Sub
strate polynucleotides or candidate HopU1 substrate poly
nucleotides may be cloned into a vector that fuses the
Substrate to an affinity tag so that it can be partially purified,
subjected to ADP-RT reactions, SDS-PAGE, and liquid
chromatography coupled with tandem mass spectrometry to
determine the mass difference between a modified or

unmodified substrate. The peptides may be analyzed with
ESI-MS-MS to identify the residues that are ADP-ribosy
lated. The amino acid or amino acids that is/are modified

within the substrate may be altered with site-directed
mutagenesis, purified with affinity chromatography and
retested in ADP-RT assays to confirm that the modified
HopU1 substrate is no longer ADP-ribosylated by HopU1.
The modified HopU1 substrate lacking residues that are
ADP-ribosylated by HopU1 may be introduced into a plant
either transiently or transgenically and over-expressed into a
plant to enhance the innate immune response.
0112 Enhancement of the plants innate immune
response may be achieved through over-expression of one or
more HopU1 substrates. As discussed above, one of skill
will recognize the appropriate expression vector and pro
moter to use to express the HopU1 substrate. Exemplary
promoters for this embodiment include constitutive promot
ers or promoters that are preferentially active in all or most
plant tissues including, for example, those active in tissues
of leaves, stems and roots.

0113 Leaf-preferred and stem-preferred promoters are
known in the art. See, for example, Yamamoto et al. (1997)
Plant J. 12(2):255-265; Kwon et al. (1995) Plant Physiol.
105:357-67: Yamamoto et al. (1995) Plant Cell Physiol.
35(5):773-778; Gotor et al. (1993) Plant J. 3:509-18:
Orozco et al. (1993) Plant Mol. Biol. 23(6):1129-1138;
Baszczynski et al. (1988) Nucl. Acid Res. 16:5732; Mitra et
al. (1995) Plant Molecular Biology 26:35-93; Kayaya et al.
(1995) Molecular and General Genetics 258:668-675; and
Matsuoka et al. (1993) Proc. Natl. Acad. Sci. USA
90(20):9586-9590. Senescence regulated promoters are also
of use, such as, SAM22 (Crowell et al. (1992) Plant Mol.
Biol. 18:559-566). See also U.S. Pat. No. 5,589,052, herein
incorporated by reference.
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0114 Root-preferred promoters are known and can be
selected from the many available from the literature or
isolated de novo from various compatible species. See, for
example, Hire et al. (1992) Plant Mol. Biol. 20(2):207-218
(Soybean root-specific glutamine synthetase gene); Keller
and Baumgartner (1991) Plant Cell 3(10): 1051-1061 (root
specific control element in the GRP 1.8 gene of French
bean); Sanger et al. (1990) Plant Mol. Biol. 15(3):533-553
(root-specific promoter of the mannopine synthase (MAS)
gene of Agrobacterium tumefaciens); and Miao et al. (1991)
Plant Cell 3(1): 11-22 (full-length cDNA clone encoding
cytosolic glutamine synthetase (GS), which is expressed in
roots and root nodules of soybean).
0115 Exemplary transfection or transformation tech
niques to achieve over-expression are described elsewhere
in the specification. Modulation of HopU1 substrate expres
sion in a plant or plant cell provides a novel strategy for
enhancing the innate immune system of a plant exposed to
a biotic stress. The evaluation of the effect of HopU1
Substrate over-expression on the plants innate immune
response to a biotic stress may also include evaluation of
phenotypic changes. As described in Example 2, plants may
be treated with bacterial flagellin flg22 as a biotic stress to
trigger the innate immune response. Examples of phenotypic
changes to a biotic stress include but are not limited to
maintained or increased callose deposition, elicitation of the
HR, oxidative burst (ROS levels), phenolic accumulation,
and decreased pathogen multiplication or disease symptoms
of the pathogen. In one aspect, the phenotypic changes are
measured as compared to a control that does not have
over-expression of the HopU1 substrate. In one aspect, the
phenotypic changes are measured as compared to a control
that over-expresses both HopU1 and the HopU1 substrate.
EXAMPLES

Example 1
hop U1 Encodes a Putative ADP-RT
0116) To begin to characterize the DC3000 effector genes
that potentially encode ADP-RTs we focused on hopU1,
which is downstream of an apparent type III promoter and
the shclf type III chaperone gene and the hopF2 effector gene
in the DC3000 chromosome (FIG. 1b). Semi-quantitative
RT-PCR experiments indicated the hopU1 gene is tran
scribed and its expression was elevated when DC3000 was
grown in a medium that induces the expression of the T3SS
(FIG. 1c). Three regions of HopU1 share similarity with
known ADP-RTS (FIG. 1a). HopU1 was type III-injected
into plant cells based on adenylate cyclase translocation
assays (FIG. 11a). A DC3000 AhopU1 mutant was reduced
6 fold in its ability to multiply in plant tissue and cause
disease symptoms in A. thaliana Col-0 (FIG. 11b).
Example 2
HopU1 Suppresses Plant Innate Immunity
0117 We earlier reported that DC3000 mutants defective
in type III effectors that can Suppress the hyperSensitive
response (HR), a programmed cell death of plant cells
associated with innate immunity, often display an enhanced
ability to elicit an HR (Jamir, Y. et al. Identification of
Pseudomonas Syringae type III effectors that Suppress pro
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grammed cell death in plants and yeast. Plant J. 37:554-565
(2004)). To investigate whether the AhopU1 mutant shared
this phenotype we infiltrated wild type DC3000 and the
AhopU1 mutant at different cell densities into Nicotiana
tabacum cv. Xanthi (tobacco). We consistently found that
the AhopU1 mutant elicited an HR in tobacco at cell
densities below the threshold needed for wild type DC3000
(FIG. 2a). When hopU1 was expressed in trans in the
AhopU1 mutant it complemented this phenotype (FIG. 2a).
We also assessed cell death by measuring the amount of ion
leakage from plant cells and found that the AhopU1 mutant
caused more cell death than DC3000 and expression of
hopU1 in trans reduced the amount of cell death to wild type
levels (FIG. 11a). Taken together, these results provide
genetic evidence that HopU1 acts as a Suppressor of the
nonhost HR.

0118. To determine whether the predicted ADP-RT activ
ity of HopU1 was required for suppression of the HR, we
ectopically expressed in the AhopU1 mutant a HopU1
derivative (HOPU 1) that had its glutamic acid residues in
its putative ADP-RT active site (FIG. 1a) substituted with
aspartic acids. This strain elicited an enhanced HR similar to
the AhopU1 mutant control Suggesting that the Suppression
of the HR required a functional ADP-RT active site (FIG.
2b). Ion leakage conductivity assays indicated that the
AhopU1 mutant expressing HopU1 caused similar
amounts of cell death as the AhopU1 mutant control (FIG.
12b). Thus, the HR suppression activity of HopU1 requires
a functional ADP-RT catalytic site.
0119 We reasoned that HopU1 may be capable of Sup
pressing other innate immune responses. To test this we
generated transgenic A. thaliana Col-O plants that constitu
tively produced HopU1 fused to a hemagglutinin epitope
(HopU1-HA). Bacterial flagellin often acts as a pathogen
associated molecular pattern (PAMP), a conserved molecule
from a microorganism recognized by animal and plant
innate immune systems (Numberger, T., Brunner, F. Kem
merling, B. & Piater, L. Innate immunity in plants and:
striking similarities and obvious differences. Immunol. Rev.
198:249-266 (2004); Akira, S., Uematsu, S. & Takeuchi, O.
Pathogen recognition and innate immunity. Cell 124:783
801 (2006); and Jones, J. D. & Dangl, J. L. The plant
immune system. Nature 444:323-329 (2006)). A conserved
peptide from bacterial flagellin, flg22, has been shown to be
effective at triggering callose (B-1-3 glucan) deposition
(Gomez-Gomez, L., Felix, G. & Boller, T. A single locus
determines sensitivity to bacterial flagellin in Arabidopsis
thaliana. Plant J. 18:277-284 (1999)). The HopU1-HA
expressing transgenic plants treated with flg22 produced
significantly reduced amounts of callose compared to wild
type plants (FIGS. 2c and d). These plants also elicited a
delayed atypical HR in response to the type III effector
AvrRpt2, which is recognized by the RPS2 resistance pro
tein present in A. thaliana Col-0 (Whalen, M. C., Innes, R.
W., Bent, A. F. & Staskawicz, B. J. Identification of

Pseudomonas Syringae pathogens of Arabidopsis and a
bacterial locus determining avirulence on both Arabidopsis
and soybean. Plant Cell 3:49-59 (1991)) (FIG. 13). Together
these data indicate that HopU1 can Suppress innate immune
responses that are triggered by both a type III effector
protein or a PAMP.
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Example 3
HopU1 is an Active ADP-RT
0120) To explore whether HopU1 indeed possessed ADP
RT activity we purified recombinant HopU1 and the cata
lytic site mutant (HOPU1), both fused to histidine affinity
tags (FIG.3a). The activity of recombinant HopU1-His was
tested with poly-L-arginine, an artificial Substrate for many
ADP-RTs that can modify arginine residues. HopU1-His
was capable of ADP-ribosylating poly-arginine in the pres

ence of P-NAD, while the HopU1-His mutant incor

porated radioactivity in amounts similar to the BSA control
(FIG. 3b). Therefore, HopU1 is an active ADP-RT that can
modify arginine residues.
0121 We next examined whether HopU1-His was
capable of using plant proteins as Substrates. Crude protein
extracts from the leaves of A. thaliana ecotype Col-0 and
tobacco were used in ADP-RT reactions. ADP-RT reactions

were separated by SDS-PAGE, and subjected to autoradiog
raphy (FIG. 3c). At least two proteins in A. thaliana extracts
and three in tobacco were ADP-ribosylated by HopU1-His.
No labelled products were detected from reactions using the
inactive HopU1-His (FIG. 3c). Therefore, HopU1-His
can use several Arabidopsis and tobacco proteins as Sub
Strates.

Example 4
RNA-Binding Proteins are Substrates
0122) To determine the identity of the proteins ADP
ribosylated by HopU1 in A. thaliana extracts we separated
ADP-RT reactions with two-dimensional (2D) PAGE fol
lowed by autoradiography (for representative examples, see
FIG. 14). One well separated protein spot stained with
Coomassie blue has the identical migration as a radiola
belled ADP-RT activity spot. It was analyzed with tandem
mass spectrometry and corresponded to chloroplast RNA
binding protein (CP-RBP) AtRBP31 (Ohta, M., Sugita, M.
& Sugiura, M. Three types of nuclear genes encoding
chloroplast RNA-binding proteins (cp29, cp31 and cp33) are
present in Arabidopsis thaliana: presence of cp31 in chlo
roplasts and its homologue in nuclei/cytoplasms. Plant Mol.
Biol. 27:529-539 (1995)) (Table 1). The other ADP-RT
activity spots did not co-migrate with visible Coomassie
blue-stained protein spots suggesting that these proteins
were in lower abundance. To enrich for less abundant
Substrates more concentrated A. thaliana extracts were made

and fractionated using ion exchange chromatography. ADP
RT assays were performed on aliquots of each fraction (FIG.
9b). Coomassie blue-stained protein spots that had identical
migration patterns as ADP-RT modified protein spots visible
on autoradiograms were analyzed with tandem mass spec
trometry. In total, we found three CP-RBPs and two glycine
rich RNA-binding proteins (GR-RBPs), AtGRP7 and

AtGRP8, to be ADP-ribosylated by HopU1-His (Table 1).

0123 To confirm that the identified CP-RBPs and GR
RBPs were substrates for HopU1-His, we constructed glu
tathione S-transferase (GST) fusions. Substrate-GST fusions
were partially purified with glutathione Sepharose or used as
crude lysates in ADP-RT reactions. Each of the substrate
GST fusions could act as substrates for HopU1-His (FIG.
4a). Other plant protein-GST fusion corresponding to pro
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teins neighbouring HopU1 Substrates on 2D polyacrylamide
gels were not ADP-ribosylated by HopU1-His. Thus, these
CP-RBPs and GR-RBPs indeed are in vitro Substrates for the

HopU1 ADP-RT. We did not find additional HopU1 sub
strates in our extensive mass spectrometry analyses Suggest
ing that the in vivo targets of HopU1 are among these
proteins.
0.124 CP-RBPs and GR-RBPs belong to a group of
RNA-binding proteins that all have in common an RNA
recognition motif (RRM), a protein domain demonstrated to
be necessary and sufficient for RNA binding (Burd, C. G. &
Dreyfuss, G. Conserved structures and diversity of functions
of RNA-binding proteins. Science 265:615-621 (1994); and
Jessen, T. H., Oubridge, C., Teo, C.-H., Pritchard, C. &
Nagai, K. Identification of molecular contacts between the
U1 A small nuclear ribonucleoprotein and U1 RNA. EMBO
10:3447-3456 (1991)). Localization experiments found that
HopU1-GFP (and HopU1-GUS) and the GR-RBPs AtGRP7
and AtGRP8 GFP fusion proteins were similarly localized to
the cytoplasm and possibly to the nucleus, while the CP
RBP-GFP fusions were discretely localized to the chloro
plast (FIG. 10). Because of our localization experiments and
the association of GR-RBPs with abiotic and biotic stress

(Gomez, J. et al. A gene induced by the plant hormone
abscisic acid in response to water stress encodes a glycine
rich protein. Nature 334:262-264 (1988); and Naqvi, S. M.
et al. A glycine-rich RNA-binding protein gene is differen
tially expressed during acute hyperSensitive response fol
lowing Tobacco Mosaic Virus infection in tobacco. Plant
Mol. Biol. 37:571-576 (1998)), we focused on the GR-RBPs
as putative physiological targets of HopU1.
0.125) The GR-RBP AtGRP7 and AtGRP8 are homolo
gous to each other sharing 76.9% identity and likely perform
related functions. AtGRP7 has been shown to bind RNA and

influence mRNA oscillations in response to circadian
rhythms at the post-transcriptional level (Heintzen, C.,
Nater, M., Apel, K. & Staiger, D. AtGRP7, a nuclear
RNA-binding protein as a component of a circadian-regu
lated negative feedback loop in Arabidopsis thaliana. Proc.
Natl. Acad. Sci. USA 94:8515-8520 (1997); and Staiger, D.,
Zecca, L., Wieczorek Kirk, D. A., Apel, K. & Eckstein, L.
The circadian clock regulated RNA-binding protein
AtGRP7 autoregulates its expression by influencing alter
native splicing of its own pre-mRNA. Plant J. 33:361-371
(2003)). AtGRP7 contains 14 arginine residues that repre
sent putative sites of ADP-ribosylation (FIG. 4b). We found
that the RRM domain-GST fusion was ADP-ribosylated by
HopU1-His, while the glycine-rich domain-GST fusion was
not (FIG. 4c). To determine the arginine residues required
for ADP-ribosylation, each arginine of RRM was individu
ally mutated to lysine in full length AtGRP7-GST fusions.
When arginines in positions 47 or 49 of AtGRP7 were
substituted with lysine these AtGRP7-GST derivatives were
no longer ADP-ribosylated Suggesting that one of these
residues is the site of the ADP-ribose modification while the

other may be required for substrate recognition (FIG. 4c).
Interestingly, based on the RRM domain structure in other
RNA-binding proteins both of these residues would likely be
solvent-exposed (Maris, C., Dominguez, C. & Allain, F. H.
The RNA recognition motif, a plastic RNA-binding platform
to regulate post-transcriptional gene expression. FEBS J.
272:21 18-2131 (2005)). Moreover, the arginine in position
49 is within RNP1, the most conserved region of the RRM
domain and one that has been directly implicated in RNA
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binding Burd, C. G. & Dreyfuss, G. Conserved structures
and diversity of functions of RNA-binding proteins. Science
265, 615-621 (1994)).
0126 To determine if AtGRP7 can be ADP-ribosylated
by HopU1 in planta, we co-expressed HopU1-FLAG or
HopU1-FLAG and AtGRP7-HA or AtGRP7R-HA (an
AtGRP7 derivative that cannot be ADP-ribosylated) in N.
benthamiana using Agrobacterium transient assays. After 40
h, plant extracts isolated from leaf tissue were separated on
SDS-PAGE gels and analyzed with immunoblots using
anti-FLAG or anti-HA antibodies. We consistently observed
an increase in the molecular mass of AtGRP7-HA when it

was expressed in planta with HopU1-FLAG, but not when
expressed with HopU1-FLAG or when HopU1-FLAG
was expressed with AtGRP7R-HA (FIG. 4d) suggesting
that the increased molecular mass was due to ADP-ribosy
lation. Therefore, HopU1-FLAG can ADP-ribosylate
AtGRP7-HA inside the plant cell.
Example 5
A Atgrp7 Mutant is More Susceptible
0127. To determine the involvement of AtGRP7 in plant
innate immunity we identified an A. thaliana SALK
homozygous T-DNA insertion line (Alonso, J. M. et al.
Genome-wide insertional mutagenesis of Arabidopsis
thaliana. Science 301, 653-657 (2003)) in the AtGRP7
locus, and confirmed that it did not produce AtGRP7 mRNA
and protein (FIG. 11). To determine if this mutant, desig
nated Atgrp7-1, was altered in its responses to P. syringae,
we infected wild type A. thaliana Col-0 and the Atgrp7-1
mutant plants with DC3000 and a AhrcC mutant defective in
the T3SS. DC3000 caused enhanced disease symptoms on
Atgrp7-1 mutant plants compared to wild type Col-0 (FIG.
5a). Each strain grew to higher levels in Atgrp7-1 plants
compared to wild type Col-O plants (FIG.5b), indicating that
Atgrp7-1 plants were more susceptible to P. syringae. The
growth difference was even more pronounced for the AhrcC
mutant, which is likely due to the fact that this strain cannot
inject any type III effectors, many of which Suppress innate
immunity. Importantly, we found that flig22-induced callose
deposition was reduced in Atgrp7-1 plants compared to wild
type A. thaliana Col-0 (FIG. 5c), further supporting that
Atgrp7-1 mutant plants were impaired in their innate
immune responses. Similar phenotypes were observed for an
independent T-DNA mutant designated Atgrp7-2 (FIG. 12).
Example 6
Discussion

0128 Several plant pathogen type III effectors are known
to suppress outputs of innate immunity (Abramovitch, R. B.,
Anderson, J. C. & Martin, G. B. Bacterial elicitation and

evasion of plant innate immunity. Nat. Rev. Mol. Cell. Biol.
7:601-611 (2006)). However, the enzymatic activity and
substrates for these type III effectors remain poorly under
stood (Grant, S. R. Fisher, E. J., Chang, J. H., Mole, B. M.
& Dangl, J. L. Subterfuge and Manipulation: Type III
Effector Proteins of Phytopathogenic Bacteria. Annu Rev
Microbiol 60:425-449 (2006)). Indeed, there are only two
cases that both an enzymatic activity and a Substrate for a
plant pathogen type III effector are known (Axtell, M. J. &
Staskawicz, B. J. Initiation of RPS2-specified disease resis
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tance in Arabidopsis is coupled to the AvrRpt2-directed
elimination of RIN4. Cell 112:369-377 (2003); Mackey, D.,
Belkhadir, Y. Alonso, J. M., Ecker, J. R. & Dangl, J. L.
Arabidopsis RIN4 is a target of the type III virulence effector
AvrRpt2 and modulates RPS2-mediated resistance. Cell
112:379-389 (2003); and Shao, F. et al. Cleavage of Arabi
dopsis PBS1 by a bacterial type III effector. Science
301:1230-1233 (2003)). The substrates of the HopU1 ADP
RT suggest a novel strategy utilized by bacterial pathogens
to modulate plant innate immunity by indirectly affecting
host RNA status. That is, GR-RBPs may act as key post
transcriptional regulators through either the trafficking, sta
bilization, or processing of specific mRNAS in response to
pathogen stress and the ADP-ribosylation of the GR-RBPs
by HopU1 may disrupt their activity (FIG. 13). By disabling
the function of GR-RBPs the pathogen may reduce the
amount of immunity-related mRNAs available in the plant
and tip the balance of the interaction in favor of the
pathogen.

0129. To our knowledge, this is the first demonstration of
an active ADP-RT virulence protein in a plant pathogen. The
DC3000 genome encodes at least two additional putative
ADP-RTs, HopO1-1 and HopO1-2. These ADP-RTs possess
low similarity with HopU1 and, therefore, likely target other
plant proteins. ADP-RTs are well characterized in animal
pathogens. However, the ADP-RT substrates described here
are novel. Interestingly, IpaH9.8, a type III effector from the
animal pathogen Shigella flexneri was recently shown to
bind the RRM-containing mammalian splicing factor U2AF
(Maris, C., Dominguez, C. & Allain, F. H. The RNA
recognition motif, a plastic RNA-binding platform to regu
late post-transcriptional gene expression. FEBS J. 272:21 18
2131 (2005)) resulting in the suppression of pro-inflamma
tory cytokines (Okuda, J. et al. Shigella effector IpaH9.8
binds to a splicing factor U2AF(35) to modulate host
immune responses. Biochem. Biophys. Res. Commun.
333:531-539 (2005)). The enzymatic activity of IpaH9.8 is
presently unknown. The protein targets of HopU1 and
IpaH9.8 Suggest that animal and plant pathogens may alter
RNA metabolism to quell the eukaryotic immune response.
Example 7
Methods Summary
0.130 Bacterial strains (and plasmids) and primers used
in this work are listed in Tables 2 and 3, respectively. A
AhopU1 mutant was made by homologous recombination.
Expression of hopU1 was assessed with RT-PCR (Guo, M.
et al. Pseudomonas Syringae type III chaperones ShcO1,
ShcS1, and ShcS2 facilitate translocation of their cognate
effectors and can substitute for each other in the secretion of

HopO1-1. J. Bacteriol. 187:4257-4269 (2005)). Construc
tion of A. thaliana Col-0 transgenic plants was done using
the Agrobacterium-mediated floral dip method (Bechtold,
N., Ellis, J. & Pelletier, G. In planta Agrobacterium mediated
gene transfer by infiltration of adult Arabidopsis thaliana
plants. C. R. Acad. Sci. Ser: III Sci. Paris 3.16:1194-1199
(1993)). DC3000 strains were tested for their ability to elicit
an HR on Nicotiana tabacum cv. Xanthi by infiltrating
strains resuspended in 5 mMMES (pH 5.6) at a cell density

of 1x10° or 1x10" cells/ml. Pathogenicity assays with A.

thaliana plants were performed by spray-inoculation with
bacterial Suspensions (Espinosa, A., Guo, M., Tam, V.C.,
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Fu, Z. Q. & Alfano, J. R. The Pseudomonas Syringae type
III-secreted protein HopPtol 2 possesses protein tyrosine
phosphatase activity and Suppresses programmed cell death
in plants. Mol. Microbiol. 49:377-387 (2003)). Seeds of the
Arabidopsis SALK 039556.21.25.x and SALK
051743.42.85.x lines, corresponding to the Atgrp7-1 and
Atgrp7-2 mutants, respectively, were obtained from the
Arabidopsis Biological Resource Center at Ohio State Uni
versity. A. thaliana plants were infiltrated with 1 uM offlg22
and stained with aniline blue for callose as described

(Gomez-Gomez, L., Felix, G. & Boller, T. A single locus
determines sensitivity to bacterial flagellin in Arabidopsis
thaliana. Plant J. 18:277-284 (1999)). Leaves were exam
ined with a Zeiss AXioPlan2 Imaging System microscope
with fluorescence. The poly-L-arginine assay was done as
previously described (Coye. L. H. & Collins, C. M. Identi
fication of Spy A, a novel ADP-ribosyltransferase of Strep
tococcus pyogenes. Mol. Microbiol. 54:89-98 (2004)). The
ADP-RT assay was adapted from a described protocol (Sun,
J. & Barbieri, J. T. Pseudomonas aeruginosa ExoT ADP
ribosylates CT10 regulator of kinase (Crk) proteins. J. Biol.
Chem. 278:32794-32800 (2003)0. AtGRP7-GST site-di
rected mutant constructs were made using the QuikChange
Site-Directed Mutagenesis kit (Stratagene). In planta HopU1
ADP-RT assays with AtGRP7 were done using Agrobacte
rium delivery as described (Jamir, Y. et al. Identification of
Pseudomonas Syringae type III effectors that Suppress pro
grammed cell death in plants and yeast. Plant J. 37:554-565
(2004)) and assessed with immunoblots.
Methods
Bacterial Strains and Nucleotide Primers.

0131 Bacterial strains and plasmids used in this work are
listed in Table 2. The primers used are listed in Table 3.
Construction of the DC3000 AhopU1 Mutant.
0132 A DC3000 AhopU1 mutant was made by amplify
ing a 2 kb region upstream and downstream of hopU1 using
PCR with primer sets P1058/P1059 and P1078/P1079. The
DNA fragment upstream of hopU1 was ligated into pHP45C2
using BamHI and HindIII sites. The DNA fragment down
stream of hopU1 was ligated into the pHP45C2 derivative
containing the upstream fragment using Xbal and SacI
restriction enzymes such that the hopU1 flanking regions
were on either side of an omega fragment in the same
orientation. This cassette was ligated into the broad host
range vector pRK415 using BamHI and SacI restriction
enzymes. The resulting construct was electroporated into
DC3000 and homologous recombination was selected for by
selecting for retention of the antibiotic marker linked to the
mutation, and loss of the plasmid marker. The resulting
mutant, UNL141, was confirmed with PCR using primers
that annealed to the flanking regions.
RT-PCR to Determine hop U1 Expression.
0133) The isolation of DC3000 RNA and reverse tran
scriptase PCR were performed as in Guo et al. (Guo, M. et
al. Pseudomonas syringae type III chaperones ShcO1,
ShcS1, and ShcS2 facilitate translocation of their cognate
effectors and can substitute for each other in the secretion of

HopO1-1. J. Bacteriol. 187:4257-4269 (2005)).
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Construction of A. thaliana Col-O Transgenic Plants
Expressing HopU1-HA and HopU1-HA.
0.134 hopU1 was amplified with PCR and recombined
into the Gateway entry vector pENTR/D-TOPO. Site-di
rected mutagenesis was carried out on this entry construct to
change the two glutamic acids in the ADP-RT active site to
aspartic acids using the QuikChange Site-Directed
Mutagenesis kit (Stratagene). The resulting constructs were
recombined into binary Gateway destination vectors such
that the hopU1 derivatives were downstream of a CaMV 35S
promoter, electroporated into Agrobacterium tumefaciens
C58C1, and transformed into A. thaliana Col-0 using the
Agrobacterium-mediated floral dip method (Bechtold, N.,
Ellis, J. & Pelletier, G. In planta Agrobacterium mediated
gene transfer by infiltration of adult Arabidopsis thaliana
plants. C. R. Acad. Sci. Ser. III Sci. Paris 3.16:1194-1199
(1993)). Plants were propagated through four generations
and confirmed to constitutively produce HopU1-HA or
HopU1-HA with immunoblots using anti-HA antibodies.
Plant Materials and Bioassays.
0135 P. syringae pv. tomato DC3000 strains were tested
for their ability to elicit an HR on Nicotiana tabacum cv.
Xanthi by infiltrating strains resuspended in 5 mMMES (pH

5.6) at a cell density of 1x10° or 1x107 cells/ml with a
needleless syringe. The AhopU1 mutant UNL141 strain
carrying plasmids pN1981 (encoding HopU1), pIN1982
(encoding HOPU1), or pML 123 (empty vector) were
used in HR Suppression experiments. Pathogenicity assays
with A. thaliana Col-0 and Atgrp7 mutant plants were
performed by spray-inoculation with bacterial Suspensions
that were adjusted to an ODoo of 0.2 as described (Espinosa,
A., Guo, M., Tam, V. C., Fu, Z. Q. & Alfano, J. R. The
Pseudomonas syringae type III-secreted protein HopPtol)2
possesses protein tyrosine phosphatase activity and Sup
presses programmed cell death in plants. Mol. Microbiol.
49:377-387 (2003)). Bacteria were enumerated from leaf
tissue by plating dilutions on KB plates with the appropriate
antibiotics. Seeds of Arabidopsis SALK lines SALK
039556.21.25.x and SALK 051743.42.85.x, which were

used to identify Atgrp7-1 and Atgrp7-2 mutants, respec
tively, were obtained from the Ohio State University Bio
logical Resource Center. Further description of methods
used to confirm the homozygosity of the T-DNA inserts, and
the absence of Atgrp7 RNA and AtGRP7 protein is in the
Examples 8 and 9.
Microscopic Detection of Callose Deposition.
0.136 A. thaliana Col-0 wild type, Col-0 Atgrp7 mutant
plants, and A. thaliana expressing HopU1-HA or HopU1
HA were infiltrated with 1 M offlg22. After 16 h, the leaves
were excised, cleared, and stained with aniline blue for

callose as described (Gomez-Gomez, L., Felix, G. & Boller,
T. A single locus determines sensitivity to bacterial flagellin
in Arabidopsis thaliana. Plant J. 18:277-284 (1999)).
Leaves were examined with a Zeiss AXioPlan2 Imaging
System microscope with fluorescence. The number of cal
lose depositions was determined with Quantity One software

(Bio-Rad). Twenty fields of view (each 0.56 mm) were

analyzed and averaged. The average and standard errors of
three independent assays for each treatment were recorded.
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Purification of HopU1-His and HopU1-His mutation
derivative.

0137 HopU1-His and HopU1-His mutation derivative
were affinity-purified from E. coli BL21 (DE3) using Ni
NTA resin following the manufacturers instructions
(Qiagen). Purified HopU1-His and HopU1-His were
stored in aliquots at -80° C. or on ice. HopU1-His and
HopU1-His protein concentrations were measured with
the BioRad Protein Assay Kit and the purity of the proteins
was examined by SDS-PAGE.
Poly-L-Arginine ADP-RT Assay.
0138 To determine if HopU1 ADP-ribosylated the arti
ficial Substrate poly-L-arginine we used a previously
described protocol (Coye. L. H. & Collins, C. M. Identifi
cation of Spy A, a novel ADP-ribosyltransferase of Strepto
coccus pyogenes. Mol. Microbiol. 54:89-98 (2004)). Briefly,
homo-poly-L-arginine (80 ul of 10 mg/ml in 0.1 M dimethyl

glutaric acid buffer pH 7.0), 1 uMP-NAD (GE Health

care) radiolabeled on the ribose moiety and 1 uM HopU1
His or HopU1-His were incubated at room temperature
for 1 h, suspended in 0.1 M phosphate buffer, centrifuged,
and resuspended in 250 ul of 0.1 M HCl and 500 ul 0.1 M
dimethyl glutaric acid buffer (pH 7.0). Incorporated radio
activity was determined using liquid scintillation. BSA (1
uM) was used as a control.
ADP-RT Assays with Plant Extracts and Recombinant Sub
Strates.

0.139. The ADP-RT assay was adapted from a described
protocol (Sun, J. & Barbieri, J. T. Pseudomonas aeruginosa
ExoT ADP-ribosylates CT10 regulator of kinase (Crk) pro
teins. J. Biol. Chem. 278:32794-32800 (2003)). Briefly,
approximately 10 ng of partially-purified HopU1-His was

incubated with 5 uCi of PI-NAD (1 Ci/umole) and A.

thaliana Col-0 or tobacco (N. tabacum cv. Xanthi) extracts,
E. coli extracts or 1-2 ug of partially purified recombinant
substrates. The reaction was stopped by adding SDS sample
buffer after incubation at room temperature for 1 h. Samples
were subjected to one-dimensional or two-dimensional
SDS-PAGE followed by autoradiography of dried gels.
AtGRP7-GST Plasmids and Site-Directed Mutagenesis of
AtGRP7-GST.

0140. The nucleotides corresponding to the RRM domain
and the glycine-rich domain of AtGRP7 were separately
PCR-amplified using primer sets P2578/P2579 and P2580/
P2581, respectively, and ligated into the GST vector pGEX
5X- 1. The resulting plasmids encoded an RRM domain
GST fusion (pAtGRP7-RRM) and glycine-rich domain
GST fusion (pAtGRP7-Gly). Several constructs encoding
full length AtGRP7-GST fusions in which individual argi
nine residues in the RRM domain were substituted with

lysines were made using the QuikChange Site-Directed
Mutagenesis (Stratagene). The primers used to introduce
these mutations and the resulting plasmids are listed in
Tables 2 and 3. These constructs were separately expressed
in E. coli to make lysates that contained AtGRP7-GST
derivatives, which were used in ADP-RT assays.
In Planta HopU1 ADP-RT Assays with AtGRP7 using
Agrobacterium Delivery.
0141 Agrobacterium transient co-delivery of AtGRP7
HA and hopU1-FLAG or AtGRP7-HA and hopU1-FLAG

DNA were done as described in Jamir et al (Jamir, Y. et al.
Identification of Pseudomonas syringae type III effectors
that Suppress programmed cell death in plants and yeast.
Plant J. 37:554-565 (2004)). After 40 h, plant tissue was
harvested with a No. 8 cork borer (12 mm diameter), ground
in liquid nitrogen, and resuspended in SDS sample buffer.
Samples were subjected to SDS-PAGE and immunoblot
analysis using anti-FLAG or anti-HA antibodies to deter
mine the molecular mass of AtGRP7 in the presence or
absence of active HopU1-FLAG.
Example 8
Bacterial Strains, Media, and Nucleotide Primers

0.142 Bacterial strains and plasmids used in this work are
listed in Table 2. Escherichia coli strain DH5O. was used for
general cloning and DNA manipulations and for Gateway
technology manipulations E. coli strain DB3.1 was used.
Pseudomonas syringae pv. tomato DC3000 was grown in
King's B (KB) broth at 30° C. or hrp-inducing fructose
minimal medium at 22°C. (King, E. O., Ward, M. K. &
Raney, D. E. Two simple media for the demonstration of
pyocyanin and fluorescein. J. Lab. Med. 22:301-307 (1954):
and Huynh, T.V., Dahlbeck, D. & Staskawicz, B.J. Bacterial
blight of Soybean: Regulation of a pathogen gene determin
ing host cultivar specificity. Science 245:1374-1377 (1989)).
E. coli and Agrobacterium tumefaciens C58C1 were grown
in LB broth at 37° C. and 30° C., respectively. Antibiotics

were used at the following concentrations (ug ml):

rifampicin, 100; ampicillin, 100; gentamicin, 10; kanamy
cin, 50; and spectinomycin 50. Oligonucleotide primers are
listed in Table 3.

Adenylate Cyclase Translocation Assays.
0.143. The adenylate cyclase assay used was modified
from Schechter et al. (Schechter, L. M., Roberts, K. A.,
Jamir, Y., Alfano, J. R. & Collmer, A. Pseudomonas syringae
type III Secretion system targeting signals and novel effec
tors studied with a Cya translocation reporter. J. Bacteriol.
186:543-555 (2004)). Briefly, DC3000 and the DC3000
AhrcC type III defective mutant carrying the appropriate
constructs, were infiltrated into N. benthamiana leaves at an

ODoo of 0.6 in 5 mM MES (pH 5.6) containing 100 uM
IPTG. Plants were sampled 10 h after infiltration with a 0.8
cm cork-borer. Leaf disks were ground in liquid nitrogen and
resuspended in 300 ul 0.1M HC1. Protein concentrations
were measured using the Bio-Rad protein assay (Bio-Rad)
and cyclic AMP was quantified using the Correlate-EIA
Direct cAMP Enzyme Immunoassay kit (Assay Designs)
according to the manufacturers instructions.
Plant Materials and Bioassays.
0.144 Pathogenicity assays with A. thaliana Col-0 were
performed by spray or dip inoculation with bacterial Sus
pensions that were adjusted to an ODoo of 0.2 as described
(Espinosa, A., Guo, M., Tam, V. C., Fu, Z. Q. & Alfano, J.
R. The Pseudomonas syringae type III-Secreted protein
HopPtol 2 possesses protein tyrosine phosphatase activity
and Suppresses programmed cell death in plants. Mol.
Microbiol. 49:377-387 (2003)). Bacteria were enumerated
from leaf tissue by plating dilutions on KB plates with the
appropriate antibiotics. A. thaliana Col-O plants expressing
either HopU1-HA or the catalytic mutant HopU1-HA

were infiltrated with DC3000 with or without avrRpt2 at

1x10 cells/ml. After 20h, the plants were photographed and
assessed for production of an HR.
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Ion Leakage Conductivity Assays.
0145 To determine the amount of ion leakage occurring
in plant tissue challenged with DC3000 strains we followed
a previously described protocol (Mackey, D., Holt, B. F., III,
Wiig, A. & Dangl, J. L. RIN4 interacts with Pseudomonas
syringae type III effector molecules and is required for
RPM1-mediated resistance in Arabidopsis. Cell 108: 743
754 (2002)). Briefly, tobacco (N. tabacum cv. Xanthi) was

infiltrated with bacterial strains containing 1x10° or 1x107
cells/ml. After 24 h, three 0.49 cm leaf discs were removed

and floated on 10 ml of freshwater for 1 h. The conductivity
of this water was determined with a conductivity meter.
Plasmid Constructions and Site-Directed Mutagenesis of
HopU1.
0146 The hopU1 gene was amplified with primers P687
and P688 and recombined into pENTR/D-TOPO Gateway
entry vector (Invitrogen) resulting in construct plN308. The
codons corresponding to the catalytic glutamic acid residues
of HopU1 in pl N308 were replaced with aspartic acid
codons using the QuikChange Site-Directed Mutagenesis
Kit (Stratagene) with primers P605 and P606 resulting in
construct plN742. The HopU1-CyaA and HopU1-CyaA
constructs were made by recombining plNOs and pLN742,
respectively, into the CyaA Gateway destination vector
pCPP3234 using Gateway cloning technology (Invitrogen)
to yield pLN919 and pLN920, respectively.

Example 9
0147 Two-dimensional gel analysis and ion-exchange
fractionation of Arabidopsis extracts. Twenty-five g of 6
week old Arabidopsis leaves were collected and ground with
sand in 100 ml of 50 mM MOPS, 250 mM sucrose (pH 7.2)
with 2 tablets of Complete Protease Inhibitor (Roche). The
extract was centrifuged at 12,000 g for 20 m followed by
ultracentrifugation at 100,000 g for 30 m. The supernatant
was collected and loaded into a Pharmacia FPLC and passed
through a 1 ml HiTrap Q XL anion exchange column (GE
Healthcare). Forty-five 1 ml fractions were then eluted with
a NaCl gradient ranging from 0 to 500 mM in 30 mMMOPS
(pH 8.0). ADP-ribosylation assays with HopU1-His were
carried out on aliquots of these fractions.
0148 ADP-RT reactions containing either crude Arabi
dopsis protein extracts or anion-exchange fractions were
separated on two-dimensional PAGE gels. The reaction
mixtures were precipitated by adding 85% acetone (final
concentration, V/v) at -20° C. for at least 2 h. Precipitated
proteins were suspended in isoelectric focusing buffer (8 M
urea, 2 M thiourea, 2% CHAPS, 2% Triton X-100, and 50

mM DTT). Two hundred lug of Arabidopsis extract were
loaded onto 7 cm pH 4-7 ReadyStrip IPG strips (BioRad).
After 12 h of active rehydration, proteins were focused using
the following program: step 1, 250 V for 15 m; step 2, 8000
V for 1 h (slow voltage ramping); step 3, 8000 V for 30,000
V-h; and step 4, holding at 500 V. The strip was then run in
the second dimension using SDS-PAGE and stained with
Coomassie blue G-250. Protein spots that had identical
migrations as ADP-RT activity spots were cut out and
identified using tandem mass spectrometry as described
(Rohila, J. S., Chen, M., Cerny, R. & Fromm, M. E.
Improved tandem affinity purification tag and methods for
isolation of protein heterocomplexes from plants. Plant J.
38:172-181 (2004)).

Jan. 31, 2008

HopU1-GUS. HopU1-GFP, and Substrate-GFP Fusion
Localization in Plant Cells.

0.149 Localization of HopU1 and HopU1 substrates were
analyzed by transient expression of B-glucuronidase (GUS)
or green fluorescent protein (GFP) fusion constructs. GUS
fusions were made in pRI121 (Chen, P. Y., Wang, C. K.,
Soong, S. C. & To, K. Y. Complete sequence of the binary
vector pBI121 and its application in cloning T-DNA inser
tion from transgenic plants. Mol. Breeding. 11:287-293
(2003)). High quality DNAs were coated on M-17 tungsten
particles (Bio-Rad), and bombarded on epidermal layers of
onion bulbs using the Biolistic PDS-1000/He System (Bio
Rad). The epidermal cells were allowed to recover on MS
plates at room temperature under constant light for 1 day.
The epidermal layers were stained for GUS activity as
described (Varagona, M. J., Schmidt, R. J. & Raikhel, N. V.
Nuclear localization signal(s) required for nuclear targeting
of the maize regulatory protein opaque-2. Plant Cell 4:1213
1227 (1992)), and stained cells were observed using a
brightfield microscope. HopU1 and HopU1 substrates were
fused to GFP in pKFWG2 (Karimi, M., Inze, D. & Depicker,
A. GATEWAY vectors for Agrobacterium-mediated plant
transformation. Trends Plant Sci. 7:193-195 (2002)) using
the Gateway System (Invitrogen). The fusion constructs
were transformed into A. tumefaciens C58C1, infiltrated into
N. benthamiana leaves, and observed with an Olympus
FV500 confocal laser scanning system with an upright
microscope.
Characterization of SALK lines SALK 039556.21.25.x
and SALK 051743.42.85.X.

0150. Seeds of the SALK T-DNA knock-out line,
SALK 039556.21.25.x and SALK 051743.42.85.X were

ordered from Arabidopsis Biological Resource Center at
Ohio State University. Total genomic DNA was prepared
from 4-5 week old individual plants. The homozygosity was
confirmed using PCR with genomic DNA from individual
plants. For SALK 039556.21.25.x (Atgrp7-1), primer set
P2012/P1947 was used to confirm the presence of the
T-DNA insertion and primer set P2012/P2013 was used to
amplify the wild type AtGRP7 gene. For SALK
051743.42.85x (Atgrp7-2) primer set P2456/P2457 was
used to amplify wild type AtGRP7 product and P1947/
P2457 was used to confirm the presence of the T-DNA
insertion. To confirm that AtGRP7 RNA was not present in
the Atgrp7 mutants, total RNA was prepared with Trizol
reagent (Invitrogen) following the manufacturers instruc
tions. cDNAs were amplified from total RNA using RT-PCR
at 44°C. with the RETRscript kit (Ambion Inc.) following
their instructions. The primer set P1932/P1929 was used to
confirm the absence of AtGRP7 mRNA in the homozygous
T-DNA Atgrp7-1 and Atgrp7-2 knock-out plants. We used
previously described antibodies (Heintzen, C. et al. A light
and temperature-entrained circadian clock controls expres
sion of transcripts encoding nuclear proteins with homology
to RNA-binding proteins in meristematic tissue. Plant J.
5:799-813 (1994)) referred to here as anti-GRPs to confirm
the Atgrp7 mutants lacked AtGRP7.

US 2008/0028487 A1

Jan. 31, 2008
22

Example 10
TABLE 1-continued
Tables 1-3

RNA-binding proteins (RBPs) identified with mass spectrometry
MS) to be ADP-ribosylated by HopUl-His

0151)
ADP-RT Substrate

(Accession No.)

TABLE 1.

RNA-binding proteins (RBPs) identified with mass spectrometry
MS) to be ADP-ribosylated by HopUl-His
ADP-RT Substrate

(Accession No.)
cp29-like Chloroplast
RBP (At2g37220.1)
cp31-like Chloroplast

RBP (AtsgSO2SO.1

(Atsg

.1)

AtRBP31 Chloroplast
RBP (Atag24770.1)

pI and mass
(kDa) of
protein

p and mass
(kD) of ART
activity spot

% of protein
coverage by
MS peptides'

4.8, 30.7

4.5, 25

49

4.6, 31.8

4.S. 27

37

w - ..

-

4.3, 35.7

AtGRP7 Glycine-rich

pI and mass
(kDa) of

p and mass
(kD) of ART

% of protein
coverage by

protein

activity spot

MS peptides'

5.9, 16.9

5.2, 20

27

5.3, 16.6

5.2, 17

19

RBP (At2g21660.1)
AtGRP8 Glycine-rich

RBP (Atag39260.1)

"Substrates were isolated based on their identical migration as protein
spots that possessed ADP-RT activity and identified with MS.
Calculated isoelectric points and molecular masses of identified substrates
were based on their predicted protein sequence.
Estimated isoelectric points and molecular masses were based on the
migration of protein spots with ADP-RT activity.

4.3, 32

15

The percent of coverage of the identified protein from the databases with

peptides identified from the samples analyzed with MS.

0152)
TABLE 2

Bacterial strains and plasmids used in this study
Primer
set used

Designation

Characteristics

in cloning Reference
Strains

A. tumefaciens

C58C1

Disarmed strain for transformation, Rif Gm'

Van Larebeke, N. et al.
Large plasmid in
Agrobacterium timefaciens
essential for crown

gall-inducing ability.
Nature 252, 169-170 (1974)
E. coi

BL21(DE3)

FompT gal dcm lonhsdSE (rem: an E. coli

Nowagen

DB3.1

B strain) with DE3, a , prophage carrying the T7
RNA polymerase gene
F. gyra462 endA A(Sr1-recA) mcrB mirr
hsdS20OrE-mE-) SupE44 ara14 galK2 lacY1 proA2

Invitrogen

rpsL20 (Str.) xyl5- leu mtl1

DHSC

SupE44 AlacU169(p80laczAM15) hsdR17 recA1

Life

endA1 gyraS6 thi-1 relA1, Nal'

Technologies

Wild type; spontaneous Rif

Cuppels, D. A. & Ainsworth,
T. Molecular and physiological

P.S. tomato

DC3OOO

characterization of

Pseudomonas Syringae pv.
tomato and

Pseudomonas Syringae pv.
maculicola strains that

DC3000-hrcC

UNL141

DC3000AhrcC., secretion deficient mutant,

RpCm.

DC3000 AhopU1 mutant, Rift Sp.

produce the phytotoxin
coronatine. Appl. Environ.
Microbiol. 61, 3530-3536
(1995)
Yuan, J. & He, S. Y. The
Pseudomonas Syringae Hrp
regulation and Secretion
system controls the production
and secretion of multiple
extracellular proteins.
J. Bacteriol. 178, 6399-6402
(1996)
This work
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TABLE 2-continued

Bacterial strains and plasmids used in this study
Primer
set used

Designation

in cloning Reference

Characteristics
Plasmids

pAtGRP7-Gly pGEX-5X-1 derivative that encodes the glycine
rich domain of AtGRP7 fused at its N terminus to

P2580,

This work

P2581

GST, Apr

pAtGRP7

pGEX-5X-1 derivative that encodes the RRM

RRM

domain of AtGRP7 fused at its N terminus to

P2578,
P2579

This work

GST, Apr

pAvrRpt2-600 pDSK600 derivative containing avrRpt2, Sp/Sm.

Pirhonen, M. U. et al.
Phenotypic expression of
Pseudomonas Syringaeavr
genes in E. coli is
linked to the activities of

pBI121
pCPP3234

the hrp-encoded secretion
system. Mol Plant-Microbe
Interact. 9, 252-260 (1996)

Binary vector for Agrobacterium-mediated plant
transformation. Contains 35S promoter and the

Clontech

GUS encoding uidA gene, Km'

Gateway destination vector containing the
adenylate cyclase (cyaA) gene for C-terminal

Schechter, L. M., Roberts,
K. A., Jamir, Y., Alfano,
. R. & Collmer, A.
Pseudomonas Syringae type
II secretion system targeting
signals and novel effectors
studied with a Cya

fusions, Sp/Sm.

translocation reporter.
pCPP5040

. Bacteriol. 186, 543-555
(2004)
amir, Y. et al.

pML123 derivative converted into a Gateway

destination vector, Gm.

pENTR/DTOPO

pET21 (+)
pGEX-5X-1
pHP45S2

dentification of

Pseudomonas Syringae
type III effectors that
Suppress programmed cell
death in plants and yeast.
Plant J. 37,554-565 (2004)
nvitrogen

Gateway system donor vector, Kim'
C-terminal Hiss-tag expression vector, Ap'
N-terminal GST-tag expression vector, Ap'
Vector containing an Sp/Sm' omega fragment
with transcriptional and translational terminators,
Apr SpR/SmR

Fellay, R., Frey, J. &
Krisch, H. Interposon
mutagenesis of soil and
water bacteria: a family of
DNA fragments designed for
in vitro insertional

Gateway binary vector with an N-terminal GFP

gene for GFP fusions, Sp/Sm.

pLN308

pENTRD-TOPO derivative carrying hopU1, Km. P687,

mutagenesis of Gram-negative
bacteria. Gene 52, 147-154
(1987)
Karimi, M., Inze, D. &
Depicker, A. GATEWAY
vectors for Agrobacterium
mediated plant transformation.
Trends Plant Sci. 7,
93-195 (2002)
This work

P688

pLN462

pLN742

Gateway destination binary vector for transient

pENTRD-TOPO derivative carrying hopU1,
Kim R.

pLN870

amir, Y. et al.

assays, Sp/Sm.

pET21 (+) derivative carrying hopU1, Ap'

dentification of

Pseudomonas Syringae
type III effectors that
Suppress programmed cell
death in plants and yeast.
Plant J. 37,554-565 (2004)
P605,

This work

P606

P775,

This work

P1132

pLN919

pCPP3234 derivative obtained by recombination

with plN308 carrying hopU1, Sp/Sm.

This work
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TABLE 2-continued

Bacterial strains and plasmids used in this study
Primer
set used

Designation
LN920
LN987
LN1072
LN1395
LN1492
LN1904
LN1905
LN1981
LN1982
LN1985

LN1992
LN1995
LN1998
LN1999

Characteristics

in cloning

Reference

P1132,

This work

pCPP3234 derivative obtained by recombination

with plN742 carrying hopU1, Sp/Sm.
pET21 (+) derivative carrying a hopU1
mutation, Ap'
pLN462 derivative containing hopU1 made by
recombination with plN308, Sp/Sm.
pLN462 derivative containing hopU1 made by
recombination with plN742, Sp/Sm.
pK7FWG2 derivative containing hopU1 made by
recombination with plN308, Sp/Sm.
pGEX-5X-1 derivative carrying At2g37220.1
cDNA, Ap.
pGEX-5X-1 derivative carrying AtSg50250.1
cDNA, Api
pCPP5040 derivative obtained by recombination
with plN308, Gm.
pCPP5040 derivative obtained by recombination
with plN742, Gm.
pCPP3234 derivative encoding AvrPtol-CyaA,
SpR/SmR

pGEX-5X-1 derivative carrying Atag24770.1

cDNA, Ap.
pENTRD-TOPO derivative carrying
At2g37220.1 cDNA, Km.
pENTRD-TOPO derivative carrying
At4g24770.1 cDNA, Km.
pENTRD-TOPO derivative carrying
At5g50250.1 cDNA, Km.

pK7FWG2 derivative containing At2g37220.1
cDNA made by recombination with plN1995,
SpR SmR.
pGEX-5X-1 derivative carrying Atag39260.1

(AtGRP8) cDNA, Apt
pGEX-5X-1 derivative carrying At2g21660.1
(AtGRP7) cDNA, Api
pENTRD-TOPO derivative carrying hopU1 with
a C-terminal FLAG fusion, Km.

P1273

This work
This work
This work

P1819,

This work

P1820

P1821,

This work

P1822

This work
This work

Fu, Z. Q., Guo, M. & Alfano,
. R. Pseudomonas Syringae
Hrp is a type III secreted
protein that is required for
plant pathogenesis, injection
of effectors, and secretion
of the HrpZ1 harpin. J.
Bacteriol. 188, 6060-6069
(2006)
P1889,

his work

P1890

P1951,

This work

P1952

P1917,

This work

P1918

P1923,

This work

P1924

This work

P1895,

his work

P1896

P1929,

his work

P1932

P531,

his work

P687

pLN462 derivative containing hopU1 with a C
erminal FLAG tag made by recombination with

his work

pLN2028, Spr/Smr

pENTRD-TOPO derivative carrying

At2g21660.1 (AtGRP7) cDNA, Km.
pENTRD-TOPO derivative carrying
AtAg39260.1 (AtGRP8) cDNA, Km.

P1925,

his work

P1926

P1927,

his work

P1928

pK7FWG2 derivative containing At2g21660.1
(AtGRP7) cDNA made by recombination with

his work

pLN462 derivative containing At2g21660.1
(AtGRP7) cDNA made by recombination with

his work

pK7FWG2 derivative containing Atag39260.1
(AtGRPS) cDNA made by recombination with

his work

pK7FWG2 derivative containing AtSg50250.1
cDNA made by recombination with plN1999,

his work

PLN2059, SpR/SmR

pLN2059, Sp/Smr

pLN2061, Sp/Sm.

SpR SmR

pENTRD-TOPO derivative carrying hopU1

with a FLAG coding sequence, Kim'
LN2094

pBI121 derivative containing hopU1 for HopU1

P605,

his work

P606

his work

GUS localization, Km.
LN21.78

pLN462 derivative containing hopU1 with a C
erminal FLAG fusion made by recombination

with plN2O86, Spr/Smir

his work
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TABLE 2-continued

Bacterial strains and plasmids used in this study
Primer
set used

Designation
LN2256

in cloning Reference

Characteristics

pK7FWG2 derivative containing Atag24770.1
cDNA made by recombination with pLN1998,

his work

SpR/SmR

LN2433

bRK415 derivative containing a hop U1

nonpolar

deletion mutation, Tc, Sp.

P1058,

This work

P1059

P1078,
P1079
LN2593
LN2594
PLN2595
PLN2596
LN2597
LN2689
LN2694
ML.123

bGEX-SX-1 deriva ive

expressing A

GST, Apr
bGEX-SX-1 deriva ive expressing A
GST, Api
bGEX-SX-1 deriva ive expressing A
GST, Apr
bGEX-SX-1 deriva ive expressing A
GST, Api
bGEX-SX-1 deriva ive expressing A
GST, Apr
bGEX-SX-1 derivative expressing At
GST, Api
bGEX-SX-1 deriva ive expressing A
GST, Apr
Broad-host-range c oning vector, Gm Km'

P2332,

This work

P2333

P2334,

This work

P2335

P2336,

This work

P2337

P2338,

This work

P2339

P2340,

This work

P2341

P2488,

This work

P2489

P2342,

This work

P2343

Labes, M., Puhler, A. &
Simon, R. A new family of
RSF1010-derived expression
and lac-fusion broad-host

pPZP212

Binary vector for transient expression, Sp/Sm.

range vectors for gram
negative bacteria. Gene 89,
37-46 (1990)
Hajdukiewicz, P., Svab, Z. &
Maliga, P. The small,
versatile pPZP family of
Agrobacterium binary
vectors for plant
transformation. Plant Mol.

Binary vector for transient expression of GFP,

pRK415

Broad-host-range vector, unstable in absence of

selection, Tc.

Biol. 25, 989-994 (1994)
Qu, F., Ren, T. & Morris,
T. J. The coat protein of
turnip crinkle virus
Suppresses posttranscriptional
gene silencing at an early
initiation step. J. Virol.
77, 511-522 (2003)
Keen, N. T., Tamaski, S.,
Kobayashi, D. & Trollinger,
D. Improved broad-host-range
plasmids for DNA cloning
in Gram-negative bacteria.
Gene 70, 191-197 (1988)

0153)
TABLE 3
Primer information
Primer

Features

Sequences of primer

or uses

P 605

5'-AAGCGCCCTCAGATGAAGATATCATGCTACCCATG-3'

HupU1DD-f

P606

5'-CATGGGTAGCATGATATCTTCATCTGAGGGCGCTT-3'

HopU1-r

P687

5'-CACCCAACAACCTAATAGTAGAACAATGAATATA-3'

Gateway

P688

5'-AATCTGACTTAATACAAATAAATGCTTTCCTT-3'

Gateway

ale
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-continued
&2 11s LENGTH 35
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 2

catgggtagc atgatatott Catctgaggg cqctt

35

<210> SEQ ID NO 3
&2 11s LENGTH 34
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 3

cacccaacaa cctaatagta gaacaatgaa tata

34

<210> SEQ ID NO 4
&2 11s LENGTH 33
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 4

aatctgacitt aatacaaata aatgctttcc titc
<210

33

SEQ ID NO 5

&2 11s LENGTH 27
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 5

cacaagct to go acataa.ca acggtga

27

<210> SEQ ID NO 6
&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 6

atgaggatcc ggatgggCat gct cqaag
<210

28

SEQ ID NO 7

&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 7

atgaaagctt agg cagttgt c gattitat
<210

SEQ ID NO 8

&2 11s LENGTH 30
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

28
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-continued

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 8

atat citagag to catgaagg aggcc.gtacg
<210

30

SEQ ID NO 9

&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 9

atgaga.gcto goctotcacg acgcc act

28

<210> SEQ ID NO 10
&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 10

agtact.cgag aatctgacitt aatacaaa

28

<210> SEQ ID NO 11
&2 11s LENGTH 18
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 11

gcaaatagog g gttactic

18

<210> SEQ ID NO 12
&2 11s LENGTH 18
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 12

gtotgg.cgca togcacat

18

<210> SEQ ID NO 13
&2 11s LENGTH 26
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 13

cacaagcttcaacaaccitaa tagtag
<210> SEQ ID NO 14
&2 11s LENGTH 33
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 14

26
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-continued
cgcggatcca aatgaatata aatcgacaac toc
<210

33

SEQ ID NO 15

&2 11s LENGTH 27
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 15

cc.gcto gagt caaatctgac ttaatac

27

<210> SEQ ID NO 16
&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 16

agtagaattic atggctgctt cagottcg
<210

28

SEQ ID NO 17

&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 17

agtact.cgag to aatattgg cqc cittgg

28

<210> SEQ ID NO 18
&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 18

agtaggat.cc tdatgactitc titcagtac
<210

28

SEQ ID NO 19

&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 19

agtact.cgag toaacgc.citt gttcgttc

28

<210> SEQ ID NO 20
&2 11s LENGTH 30
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 20

agtaggat.cc tdatggct to ttctatagitt
<210> SEQ ID NO 21

30
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&2 11s LENGTH 2.8
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 21

agtact.cgag ttaatatoca C gocttgg

28

<210> SEQ ID NO 22
&2 11s LENGTH 30
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 22

agtc gaattic atgtctgaag titgagtaccg

30

<210> SEQ ID NO 23
&2 11s LENGTH 29
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 23

agtcCtcgag ttaccago.cg CCaccaccg

29

<210> SEQ ID NO 24
&2 11s LENGTH 26
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 24

caccaacaat ggcttcttct atagitt

26

<210> SEQ ID NO 25
&2 11s LENGTH 18
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 25

atat coacgc cittggagg

18

<210> SEQ ID NO 26
&2 11s LENGTH 26
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 26

caccaacaat gacittcttca gtacta
<210

SEQ ID NO 27

&2 11s LENGTH 18
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

26
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OTHER INFORMATION: Artifical sequence - Primer
<400 SEQUENCE: 27

acgccttgtt cqttccitc

18

SEQ ID NO 28
LENGTH
TYPE

26
DNA

ORGANISM: Artificial sequence
FEATURE:

OTHER INFORMATION: Artifical sequence - Primer
<400 SEQUENCE: 28

caccaacaat gg.cgtocggit gatgtt

26

SEQ ID NO 29
LENGTH
TYPE

18
DNA

ORGANISM: Artificial sequence
FEATURE:

OTHER INFORMATION: Artifical sequence - Primer
<400 SEQUENCE: 29
ccatcc tocca coaccacc

18

SEQ ID NO 30
LENGTH
TYPE

26
DNA

ORGANISM: Artificial sequence
FEATURE:

OTHER INFORMATION: Artifical sequence - Primer
<400 SEQUENCE: 30

caccaacaat gtctgaagtt gagtac

26

SEQ ID NO 31
LENGTH
TYPE

18
DNA

ORGANISM: Artificial sequence
FEATURE:

OTHER INFORMATION: Artifical sequence - Primer
<400 SEQUENCE: 31

ccago.cgc.ca ccaccgcc

18

SEQ ID NO 32
LENGTH
TYPE

2.8
DNA

ORGANISM: Artificial sequence
FEATURE:

OTHER INFORMATION: Artifical sequence - Primer
<400 SEQUENCE: 32

agtcctcgag titaccatcct coaccacc
SEQ ID NO 33
LENGTH
TYPE

29
DNA

ORGANISM: Artificial sequence
FEATURE:

OTHER INFORMATION: Artifical sequence - Primer
<400 SEQUENCE: 33

28
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cacc gaattic atggcgtc.cg gtgatgttg

29

<210> SEQ ID NO 34
<211& LENGTH 22
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 34

tggttcacgt agtgggcc at cq
<210

22

SEQ ID NO 35

<211& LENGTH 24
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 35

caccatggct gottcagott cqtc
<210

24

SEQ ID NO 36

&2 11s LENGTH 2.0
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 36

atattggcgc cittggaggcc
<210

20

SEQ ID NO 37

&2 11s LENGTH 32
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 37

agattotaga atgaatataa atcgacaact gc
<210

32

SEQ ID NO 38

&2 11s LENGTH 35
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 38

agatggat.cc aatctgacitt aatacaaata aatgc
<210

35

SEQ ID NO 39

&2 11s LENGTH 18
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 39

gccagattaa gottctgg
<210> SEQ ID NO 40

18
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&2 11s LENGTH 2.0
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 40

to gatatoac toggagtc.cg

20

<210> SEQ ID NO 41
&2 11s LENGTH 43
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 41

cgtocggtga t gttgagtat aaatgctt.cg ttggaggtot agc

43

<210> SEQ ID NO 42
&2 11s LENGTH 43
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 42

gctagaccitc Caacgaag catttatactica acatcaccgg acg

43

<210> SEQ ID NO 43
<211& LENGTH: 40
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 43

gcatgg gcca citgatgacaa agctottgag act gcctitcg

40

<210> SEQ ID NO 44
<211& LENGTH: 40
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 44

cgaagg cagt citcaagagct ttgtcatcag togcc catgc

40

<210> SEQ ID NO 45
&2 11s LENGTH 38
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 45

ccaagatcat taacgataaa gag actdgaa gatcaagg
<210> SEQ ID NO 46
&2 11s LENGTH 38
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

38
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<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 46

ccttgatctt coagtctott tatcgittaat gatcttgg

38

<210> SEQ ID NO 47
&2 11s LENGTH 38
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 47

cgatcgtgag actggaaaat caaggggatt cqgattog

38

<210> SEQ ID NO 48
&2 11s LENGTH 38
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 48

cgaatcc.gaa tocccttgat tittccagtct cacgatcg
<210

38

SEQ ID NO 49

<211& LENGTH: 40
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 49

ggacaagatc. tcgatggcaa aag catcact gttaac gagg
<210

40

SEQ ID NO 50

<211& LENGTH: 40
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 50

ccitcgittaac agtgatgctt ttgccatcga gatcttgtc.c
<210

40

SEQ ID NO 51

&2 11s LENGTH 38
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 51

gttaac gagg Ctcagtcaaa aggaag.cggt gg.cgg.cgg
<210> SEQ ID NO 52
&2 11s LENGTH 38
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 52

38
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cc.gcc.gc.cac cqctitccttt to actgagcc togttaac
<210

38

SEQ ID NO 53

&2 11s LENGTH 25
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 53

attgatcc.gg cccagtatica gttgt

25

<210> SEQ ID NO 54
&2 11s LENGTH 2.0
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 54

ccagat cago: aaaacaatcc
<210

20

SEQ ID NO 55

&2 11s LENGTH 39
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 55

cgtgag acto gaagatcaaa aggattcgga titcgtcacc
<210

39

SEQ ID NO 56

&2 11s LENGTH 39
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 56

ggtgac gaat cogaatccitt ttgat cittcc agt citcacg
<210

39

SEQ ID NO 57

&2 11s LENGTH 25
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 57

cgcgaattica togcgtc.cgg to atg
<210

25

SEQ ID NO 58

&2 11s LENGTH 34
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 58

taagaatgcg gcc.gctaatc gtgactgagc citcg
<210

SEQ ID NO 59

34
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&2 11s LENGTH 23
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 59

gc gaatticca gtcacgagga agc
<210

23

SEQ ID NO 60

<211& LENGTH 22
&212> TYPE DNA

<213> ORGANISM: Artificial sequence
&220s FEATURE

<223> OTHER INFORMATION: Artifical sequence - Primer
<400

SEQUENCE: 60

gggatccitta coatccitcca co

22

<210> SEQ ID NO 61
&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 61

Gly Thr Pro Leu Tyr Arg Glu Val Asn. Asn Tyr Lieu Arg
1

5

10

<210> SEQ ID NO 62
&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 62

Gly Gly Arg Tyr Val Glu Pro Ala Phe Met Ser Thr Thr Arg Ile Lys
1

5

10

15

Asp Ser Ala
<210

SEQ ID NO 63

<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 63

Ile Ser Gly Ser Ser Glin Ala Pro Ser Glu Glu Glu Ile Met
1

5

10

<210> SEQ ID NO 64
&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 64

Thir Ser Cys Lieu. Tyr Arg Pro Ile Asn His His Leu Arg
1

<210

5

10

SEQ ID NO 65

&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 65

Gly Asn Thr Tyr Arg Asp Asp Ala Phe Met Ser Thr Ser Thr Arg Met
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1

5

10

15

Asp Val Thr
<210

SEQ ID NO 66

<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 66

Ile Gly Pro Phe Ser Lys Asn Pro Tyr Glu Asp Glu Ala Lieu
1

<210

5

10

SEQ ID NO 67

&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 67

Thir Ser Cys Lieu. Tyr Arg Pro Ile Asn His His Leu Arg
1

<210

5

10

SEQ ID NO 68

&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 68

Gly Lys Thr Tyr Arg Asp Glu Ala Phe Met Ser Thr Ser Thr His Met
1

5

10

15

Glin Wal Ser

<210

SEQ ID NO 69

<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 69

Ile Gly Pro Phe Ser Lys Asn Pro Tyr Glu Asp Glu Ala Lieu
1

<210

5

10

SEQ ID NO 70

&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 70

Gly Asp Arg Lieu. Tyr Arg Ala Asp Ser Arg Pro Pro Asp
1

<210

5

10

SEQ ID NO 71

&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 71

Gly Phe Val Arg Tyr Asp Asp Gly Tyr Val Ser Thr Ser Leu Ser Leu
1

5

Arg Ser Ala
<210

SEQ ID NO 72

10

15
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<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 72

Leu Gly Val Tyr Ser Pro His Pro Tyr Glu Gln Glu Val Ser
1

<210

5

10

SEQ ID NO 73

&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 73

Asp Asp Llys Lieu. Tyr Arg Ala Asp Ser Arg Pro Pro Asp
1

5

10

<210> SEQ ID NO 74
&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 74

Gly Phe Val Arg His Asp Asp Gly Tyr Val Ser Thr Ser Ile Ser Leu
1

5

10

15

Arg Ser Ala
<210

SEQ ID NO 75

<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 75

Leu Gly Ala Tyr Ser Pro His Pro Asp Glu Gln Glu Val Ser
1

<210

5

10

SEQ ID NO 76

&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 76

Cys Tyr Tyr Val Tyr Arg Gly Val Arg Gly Ile Arg Phe
1

<210

5

10

SEQ ID NO 77

&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 77

Gly Lys Ser Val Tyr Phe Gly Glin Phe Thr Ser Thr Ser Leu Arg Lys
1

5

Glu Ala Thr

<210

SEQ ID NO 78

<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 78

10

15
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Ile Lys Glin Phe Ser Phe Phe Pro Ser Glu Asp Glu Val Leu
1

<210

5

10

SEQ ID NO 79

&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 79

Asp Met Lys Val Tyr Arg Gly Thr Asp Lieu. Asn Pro Leu
1

<210

5

10

SEQ ID NO 80

&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 80

Gly Lys Thr Phe Lys Asp Asp Gly Phe Met Ser Thr Ala Lieu Val Lys
1
Glu Ser Ser

5

10

15

<210> SEQ ID NO 81
<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400> SEQUENCE: 81

Val Ser Lys Ile Ser Tyr Phe Pro Asp Glu Ala Glu Lieu Lieu
1

5

10

<210> SEQ ID NO 82
&2 11s LENGTH 13
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 82

His Arg Val Val Tyr Arg Gly Lieu Lys Lieu. Asp Pro Lys
1

<210

5

10

SEQ ID NO 83

&2 11s LENGTH 19
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 83

Gly Asn. Ile Ile Ile Asp Lys Ala Phe Met Ser Thr Ser Pro Asp Lys
1

5

10

Ala Trp Ile
<210> SEQ ID NO 84
<211& LENGTH: 14
&212> TYPE PRT

<213> ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 84

Leu Gly Asp Val Ala His Phe Lys Gly Glu Ala Glu Met Lieu
1

<210

5

SEQ ID NO 85

&2 11s LENGTH 13
&212> TYPE PRT

10

15
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<213> ORGANISM: Pseudomonas

syringae

SEQUENCE: 85

Asn Ile Thr Val Tyr Arg Trp Cys Gly Met Pro Glu Phe
1

5

10

SEQ ID NO 86
LENGTH
TYPE

19
PRT

ORGANISM: Pseudomonas

syringae

<400 SEQUENCE: 86

Asn. Thir Ile Lys Glu Asp Lys Gly Tyr Met Ser Thr Ser Leu Ser Ser
1

5

10

15

Glu Arg Lieu
SEQ ID NO 87
LENGTH
TYPE

14
PRT

ORGANISM: Pseudomonas

syringae

<400 SEQUENCE: 87

Leu Ser Ala Ile Gly Gly Phe Ala Ser Glu Lys Glu Ile Leu
1

5

10

SEQ ID NO 88
LENGTH
TYPE

13
PRT

ORGANISM: Pseudomonas

syringae

<400 SEQUENCE: 88

Val Val Lys Thr Phe Arg Gly Thr Arg Gly Gly Asp Ala
1

5

10

SEQ ID NO 89
LENGTH
TYPE

19
PRT

ORGANISM: Pseudomonas

syringae

<400 SEQUENCE: 89

Gly Lys Val Gly His Asp Asp Gly Tyr Leu Ser Thr Ser Leu Asn Pro
1

5

10

Gly Val Ala
SEQ ID NO 9 O
LENGTH
TYPE

14
PRT

ORGANISM: Pseudomonas

syringae

SEQUENCE: 9 O

Val Ser Gly Ile Ser Asn Tyr Lys Asn. Glu Lys Glu Ile Leu
5

10

SEQ ID NO 91
LENGTH
TYPE

13
PRT

ORGANISM: Pseudomonas

syringae

SEQUENCE: 91

Val Val Lys Thr Phe Arg Gly Thr Glin Gly Arg Asp Ala
5

10

15
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SEQ ID NO 92
LENGTH
TYPE

19
PRT

ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 92

Gly Glin Val Gly His Asp Ala Gly Tyr Lieu Ser Thr Ser Arg Asp Pro
1

5

10

15

Gly Val Ala
SEQ ID NO 93
LENGTH
TYPE

14
PRT

ORGANISM: Pseudomonas syringae
<400

SEQUENCE: 93

Val Ser Glu Ile Ser Ile Glu Gly Asp Glu Glin Glu Ile Leu
1

5

10

What is claimed is:

substrate of HopU1 in the presence of HopU1 and assaying

1. A method of enhancing an innate immune response of
a plant comprising:
over-expressing in the planta HopU1 Substrate capable of
being ADP-ribosylated by HopU1.
2. The method of claim 1, further comprising introducing
into a plant cell a construct comprising a polynucleotide
encoding the HopU1 substrate, wherein the HopU1 substrate
polynucleotide is operably linked to a promoter functional in
plant cells to yield transformed plant cells; and
regenerating a transgenic plant from the transformed plant
cells, wherein the HopU1 substrate is expressed in the
cells of the transgenic plant at levels sufficient to
enhance the immune response in the transgenic plant.
3. The method of claim 1, wherein the HopU1 substrates
are RNA binding proteins.
4. The method of claim 3, wherein the HopU1 substrates
comprise Glycine rich RNA binding proteins or Chloroplast
RNA binding proteins.
5. The method of claim 1, wherein the HopU1 substrates
are mutated in their ADP-ribosylation sites.
6. The method of claim 1, the biotic stresses comprise a
pathogen, bacteria, fungi, protozoa a virus, an insect,
wounding, or physical damage caused by people.
7. The method of claim 1, wherein the plant undergoes a
hypersensitive response and cells in contact with the biotic

the substrate to determine if the substrate underwent ADP

stress die.

8. The method of claim 1, further comprising identifying
a substrate of HopU1 and introducing the substrate into the
plant cell.
9. The method of claim 8, further comprising identifying
one or more HopU1 Substrates by incubating a candidate

ribosylation.
10. The method of claim 1, wherein the plant is a
dicotyledonous plant.
11. The method of claim 1, wherein the plant is a
monocotyledonous plant.
12. The method of claim 1, wherein the plant is corn,
tomato, soybean, Sunflower, Sorghum, canola, wheat, alfalfa,
cotton, rice, barley or millet.
13. The method of claim 1, wherein immune response is
enhanced as compared to a control plant, wherein the
HopU1 substrate is not over-expressed in the control plant.
14. A method of identifying a substrate of HopU1 in a
plant or animal cell comprising:
incubating an extract from a plant or animal cell Suspected
of comprising a candidate HopU1 Substrate in the
presence of HopU1 and assaying the Substrate to deter
mine if the candidate HopU1 substrate underwent
ADP-ribosylation.
15. The method of claim 14, wherein the candidate

HopU1 substrate is a RNA binding protein.
16. The method of claim 15, wherein the RNA binding
protein is a glycine rich RNA binding protein.
17. The method of claim 14, wherein HopU1 ribosylates
the candidate HopU1 substrate in the presence of NAD".
18. The method of claim 14, wherein the assaying further
comprises separating the extract on a SDS-PAGE gel and
using autoradiography to determine a molecular mass of the
candidate HopU1 substrate.
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